Patent ductus arteriosus in extremely preterm infants : characteristics, risk factors and treatment decisions by Guðmundsdóttir, Anna
Department of Women’s and Children’s Health 
Karolinska Institutet, Stockholm, Sweden 
PATENT DUCTUS ARTERIOSUS IN 
EXTREMELY 
PRETERM INFANTS – 
CHARACTERISTICS, RISK 
FACTORS AND TREATMENT DECISIONS 
Anna Guðmundsdóttir 
 
Stockholm 2019 
 
 All previously published papers were reproduced with permission from the publisher. 
Cover illustration: Rebecka Lagercrantz 
Published by Karolinska Institutet. 
Printed by E-print AB 
© Anna Guðmundsdóttir, 2019 
ISBN 978-91-7831-390-7 
Patent ductus arteriosus in extremely preterm infants – 
characteristics, risk factors and treatment decisions 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Anna Guðmundsdóttir 
Principal Supervisor: 
Associate Professor Anna-Karin Edstedt Bonamy  
Karolinska Institutet 
Department of Medicine Solna 
Unit of Clinical Epidemiology 
 
Co-supervisor(s): 
Marco Bartocci, PhD 
Karolinska Institutet 
Department of Women´s and Children´s Health 
Division of Neonatology 
 
Professor Mikael Norman 
Karolinska Institutet 
Department of Clinical Science, Intervention and 
Technology 
Division of Pediatrics 
Opponent: 
Willem de Boode, PhD 
Radboud University;  
Amalia Children's Hospital  
Nijmegen, Holland 
Department of Pediatrics 
Division of Neonatology 
 
Examination Board: 
Associate Professor Matteo Bruschettini 
University of Lund 
Department of Pediatrics 
Division of Neonatology 
 
Associate Professor Katarina Wide 
Karolinska Institutet 
Department of Clinical Science, Intervention and 
Technology 
Division of Pediatrics 
 
Professor Tine Brink Henriksen 
University of Aarhus, Aarhus 
Department of Clinical Medicine 
Division of Pediatrics 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Í minningu föður míns, Guðmundar (1942-2016) og frænku minnar Siggu (1948-2015) 
  
  
 
 
 
 
 
quid est ergo tempus? si nemo ex me quaerat, scio; si quaerenti explicare velim, nescio: 
non vere dicamus tempus esse, nisi quia tendit non esse. 
 
 
What, then, is time? If no one asks me, I know what it is. If I wish to explain it to him who 
asks me, I do not know. Thus, can we not truly say that time is only as it tends toward 
nonbeing. 
 
 
Hvað er tíminn?  Þegar enginn spyr mig veit ég það. Sé ég spurður og beðinn að skýra það 
veit ég það ekki. Í rauninni er ekki unnt að segja að tíminn sé til nema af því að hann stefnir í 
að vera ekki til. 
 
 
 
Confessiones, Augustinus 
 
 
 
English translation: Albert C. Outler 
Íslensk þýðing: Hr. Sigurbjörn Einarsson 
 
  
ABSTRACT 
Survival rates in infants born extremely preterm, before 28 weeks of gestation, are increasing 
and the focus has shifted towards decreasing morbidites after extremely preterm birth and 
promoting life-long health for the survivors.1-3Approximately 50-60% of extremely preterm 
infants have the past decade been treated for patent ductus arteriosus (PDA) to induce ductal 
closure.4,5In the abscence of ductal closure, hemodynamic changes follow which can result in 
significant systemic hypoperfusion and excessive pulmonary perfusion which has been 
associated with an increased risk of the neonatal morbidities such as intraventricular 
hemorrhage (IVH), necrotising enterocolitis (NEC), renal failure and and bronchopulmonary 
dysplasia (BPD).6 Cyclooxygenase (COX) inhibitors, ibuprofen or indomethacin, are used as 
first line of treatment to promote ductal closure.7,8 Surgical closure may be indicated if 
pharmacological therapy fails, or when contraindications to COX inhibitors are present.9 The 
theoretical rationale for PDA treatment is unquestionable, but trials showing long-term 
benefits from PDA treatment are scarce.10-12 In this thesis, paper I-III are cohort studies 
conducted in Sweden and in Europe. The study in paper IV is a hospital-cohort study in 
Stockholm. The overall aim of the studies is to investigate PDA incidence, neonatal 
characteristics associated with PDA closure or treatment, variation in treatment strategies, 
and association with neonatal outcomes. Furthermore, to evaluate the role of cardiac 
biomarkers in predicting PDA closure. 
In paper I, the aim was to investigate if timing of pharmacological PDA treatment (at 0-2 
days, 2-6 days or ≥7 days of age) was associated with risk of later PDA surgery or death; or 
risk for BPD at 36 weeks postmenstrual age (PMA). This was investigated in the population-
based prospective Extremely Preterm Infants in Sweden (EXPRESS) cohort (infants born at 
<27 weeks of gestation during 2004-2007).13 Two hundred ninety of 585 children were 
treated pharmacologically, of whom 102 later underwent PDA surgery. In a model stratified 
on GA and adjusted for clustering on region, hazard ratios (HR) for late and intermediate vs 
early start were 1.10 [CI 0.53–2.28] and 0.89 [CI 0.57–1.39] respectively. Compared to early 
start, the risk of BPD after late start of PDA treatment was associated with a significantly 
lower risk of BPD odds ratio (OR) 0.29 [CI 0.13-0.61] in a model stratified on gestational age 
(GA) and adjusted for sex and small for gestational age (SGA). 
In paper II, the aim was to investigate incidence and variation in PDA treatment and 
association with BPD at 36 weeks PMA or death; and survival without major neonatal 
morbidity. This was performed in a large European cohort (the EPICE study) of infants born 
at <32 weeks of gestation during 2011-2012, including 6898 infants.14 The results show that 
there is significant variation of 10% to 39% in PDA treatment between the different regions 
(p<0.001). The regions were categorized according to low (<15%, n = 6), medium (15–25%, 
n = 9), or high (>25%, n = 4) proportion of PDA treatment. The difference in PDA treatment 
could not be explained by differences in perinatal characteristics between these regions.  
Infants treated for PDA, compared to those not treated, were at higher risk of BPD or death in 
all regions, with an overall propensity score adjusted risk ratio of 1.33 [95% confidence 
interval 1.18–1.51]. Survival without major neonatal morbidity was not related to PDA 
treatment.  
In paper III, the neurodevelopmental outcome after PDA treatment was studied. In the 
EXPRESS cohort (see paper I), the survivors at 6.5 years of age had an extensive 
neurodevelopmental follow-up.15 Four hundred and thirty five of 486 children had available 
data on both PDA treatment and neurodevelopmental outcome. PDA treatment as an 
exposure was categorized as no PDA treatment; pharmacological PDA treatment; PDA 
surgery after prior pharmacological treatment; and primary PDA surgery. The outcomes 
studied were NDI (by the definition of Moore16) and the full-scale intelligent quotient (FSIQ) 
as measured by Wechsler Intelligent Scale for Children (WISC-IV17). No increased risks of 
adverse neurodevelopment were found among children treated pharmacologically for PDA, 
regardless of whether they later had surgical PDA closure or not. The risk of moderate to 
severe NDI was higher among children treated with primary PDA surgery in the adjusted 
model than in extremely preterm children not receiving PDA treatment, IRR 1.62 [95% CI 
1.28-2.06] p<0.001 and a lower FSIQ, adjusted mean difference -7.1 [95% CI -11 till -3.2] 
p<0.001. Timing of PDA surgery was investigated as an exposure in the children undergoing 
PDA surgery. Children having PDA surgery at <10 days of age (irrespective if primary or 
after prior pharmacological treatment), compared to at >20 days of age, had increased risk for 
moderate to severe NDI, IRR 3.26 [95% CI 2.40 to 4.42] p<0.001; and adjusted mean 
difference of FSIQ -15 [95% CI-19 till -12] p<0.001.    
In paper IV, the perinatal characteristics associated with spontaneous PDA closure were 
investigated in a hospital-based cohort of extremely preterm infants in Stockholm. The 
association of the biomarkers N-Terminal fragment-pro-Brain Natriuretic Peptide (NT-
proBNP) and cardiac Troponin T (cTnT) with spontaneous closure and all types of PDA 
treatment was investigated. Fifty-eight of 98 infants were treated for PDA with a median age 
at start of treatment of 8 days (interquartile range, IQR 5-11). Six (6%) infants closed their 
PDA at ≤7 days of age. All infants who closed their duct spontaneously were born at ≥25 
weeks of gestation. Higher NT-proBNP values on day 3 were associated with later need of 
PDA surgery and lower levels were associated with PDA closure without any PDA treatment.  
In conclusion, there is large variation in PDA treatment across Europe which is not associated 
with perinatal characteristics. This indicates need of standardization of diagnostics and 
treatment. In all four studies, the strongest predictor for PDA treatment is GA and the 
spontaneous closure rate in extremely preterm infants born at ≥25 weeks is relatively high. A 
more conservative approach with later start of PDA treatment is not associated with increased 
risks of morbidity and PDA treatment is not associated with decreased risk of survival 
without major morbidities. PDA pharmacological treatment with or without later surgery is 
not associated with adverse neurodevelopment. PDA surgery at <10 days of age and primary 
PDA surgery are associated with increased risk of adverse neurodevelopment. More precise 
PDA diagnostic criteria and are needed in future studies. NT-proBNP may be useful as an 
additional parameter in combined scores of clinical and echocardiographic markers of ductal 
severity. Optimally designed, blinded placebo-controlled studies with a clear definition of the 
PDA exposure and related outcomes are needed to understand the PDA in extremely preterm 
population  
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1 INTRODUCTION 
Prematurity is defined by the World Health Organization as birth before 37 weeks of 
gestation.18 It is further categorized into: late or moderately preterm infants, born at 32-36 
weeks; very preterm born at less than 32 weeks of gestation and extremely preterm born at 
less than 28 weeks.19  Preterm birth rates vary between countries but a global estimation 
rate is approximately 11%.19 In Europe, a rate of 5-11% has been established and in 
Sweden preterm birth accounts for 5-6% of all births and extremely preterm births account 
for 0.3-0.4% of all births.19-21 In the last decades, advances in neonatal intensive care have 
greatly increased the survival in this group, particularly in countries with a highly 
developed health care system. Infants born extremely preterm have a higher risk of 
morbidity and mortality compared to those born at term.4,13 With increasing survival rates 
in this group, the focus has shifted more towards decreasing morbidity and promoting life-
long health for the survivors of extremely preterm birth. Patent ductus arteriosus (PDA) is 
one of the factors that can lead to morbidity as it is the most common circulatory problem 
in extremely preterm infants.6 Historically 50-60% of infants born before 28 weeks of 
gestation have been treated for PDA to induce ductal closure.4,5 In the abscence of ductal 
closure, hemodynamic changes follow where blood is shunted from the systemic circulation 
to the pulmonary circulation. In severe cases this results in significant systemic 
hypoperfusion and excessive pulmonary perfusion which has been associated with an 
increased risk of the neonatal morbidities such as intraventricular hemorrhage (IVH), 
necrotising enterocolitis (NEC), renal failure and and bronchopulmonary dysplasia 
(BPD).6,7 Until recently, active PDA closure was considered beneficial.10,11,22 
Cyclooxygenase inhibitors, ibuprofen or indomethacin, are used as first line of treatment to 
promote ductal closure.7,8 Surgical closure may be indicated if pharmacological therapy 
fails, or when contraindications to cyclooxygenase inhibitors are present.9,23  The 
theoretical rationale for PDA treatment is unquestionable, but trials showing long-term 
benefits from PDA treatment are scarce.10 Moreover, surgical closure has been associated 
with adverse outcome though it has been debated that these studies have had problems with 
confounding by indication.24-28On the other hand, spontaneous PDA closure has recently 
been shown to be high, even among the most immature infants.29-32 Early treatment of PDA 
might thus expose infants, in whom ductus ultimately would close spontaneously, to 
unnecessary treatment with potent and potentially toxic drugs. The overall aim of this 
project is explore the incidence of PDA treatment in cohorts of very and extremely preterm 
infants, risk factors for treatment and associations with neonatal outcomes.  Furthermore, 
the aim is to explore clinically relevant and objective diagnostic criteria for PDA in infants 
born extremely preterm.  The purpose is to better characterize infants in whom benefits of 
treatment might outweigh the risks with treatment, both in the short- and long-term. 
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2 BACKGROUND 
2.1 PATENT DUCTUS ARTERIOUSUS 
 
 
Figure 2.1. A four chamber view of the heart with the right and left atriums and right 
and left ventricles communicating with the great vessels, the pulmonary artery (PA) and 
aorta (Ao). The ductus arteriosus (DA) is a vessel connecting the PA and the Ao. 
Published with permission from ©Stefan Johansson. 
The ductus arteriosus (DA) is a fetal vessel that connects the main pulmonary artery (PA) 
with the descending aorta (Ao) and is necessary for the fetal circulation.33 In fetal life, the 
diameter of the DA is similar to that of the the descending Ao.6 Functionally, the DA 
provides a bypass of the pulmonary blood flow to the descending Ao. i.e. the blood streaming 
from the placenta to the right atrium through the foramen ovale, to the left atrium and further 
to the left ventricle and out to the Ao. From the right ventricle the blood flows to the PA and 
as the resistance is high there, it flows through the open duct to the descending Ao.6  In the 
newborn infant the DA usually closes in the first one to three days after birth.33,34 A patent 
ductus arteriosus is when the DA closure is delayed (PDA). Ductal closure may be delayed in 
infants born with duct dependent congential heart diseases or persistent pulmonary 
hypertension for example due to meconium aspiration, congenital sepsis or asphyxia.6 
Furthermore, a reason for a PDA can be congenital, i.e. an anatomical PDA.34 When the PDA 
has hemodynamic consequences it is defined as a hemodynamically significant PDA 
(hsPDA).34,35 It has become more evident that genetics are a contributing factor in ductal 
patency in term and probably in preterm infants also.33,36 In term infants an incidence of 
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approximately 0,5% has been described and it is more common in females than males.37 
Finally, ductal closure is delayed in preterm infants compared to full term infants.6,33,34  
 
2.2 MECHANISMS OF DUCTAL CLOSURE IN FULL TERM AND PRETERM 
INFANTS 
Fetal life 
During later stages of pregnancy, the vasodilating prostaglandins (PG), especially 
prostaglandin E2 (PGE2 )maintain the ductus arteriosus (DA) open.
6  
At birth in full term infants 
Ductal closure is described as occurring in two phases: functional and anatomical, with the 
former taking place during the first hours of life and the latter in the first week(s) of life.6  
The mechanisms conducting the closure are initiated and balanced by many factors. 
 
• Functional closure occurs when the smooth muscle cells in the vessel wall 
constrict and the lumen narrows. This is determined by balancing factors such as 
oxygen tension, levels of vasoconstrictors (such as endothelin and 
catecholamines) and levels of vasodilators (such as PGs and nitric oxide (NO)), 
and finally the intraluminal pressure in the DA.33,38,39 After birth there is a 
decrease in circulating PGE2 due to increased removal by the lungs together with 
the cease in supply from the placenta once the umbilical cord is clamped.6 Also, 
the PGE2 sensitivity in the ductal wall decreases.
6,33,34 Furthermore, in the initial 
functional closure, platelets are believed to have a role in “sealing” the DA, 
which further promotes closure.33,40 
• Anatomical closure is the remodeling of the lumen and vessel wall tissue, which 
follows the initial functional constriction of the duct.41,42  
At birth in preterm infants 
In preterm infants, especially the most immature group, the normal signals impaired and the 
mechanisms for ductal closure are delayed (discussed later).6,33,34,41,43,44 The circulatory 
transition after birth together with the immature lungs is part of the explanation for this.33 
• Ductus arteriosus (DA): It is normal to be born with an open DA and during 
normal transition it closes spontaneously within the the first few days.  
• Patent ductus arteriosus (PDA): The delayed process of closure results in a PDA. 
• Hemodynamic significant ductus arteriosus (hsPDA): A PDA with hemodynamic 
consequences on the heart and circulation is defined as a hsPDA. 
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Furthermore, it has been shown that the DA in preterm infants is more sensitive to the 
vasodilating effects of PGE2 as well as NO.
45 This impairs the anatomical closure, as the 
vasoconstriction of the vessel is not prominent enough to induce the anatomical changes 
necessary for permanent closure.33  
2.3 TREATMENT STRATEGIES FOR PDA CLOSURE 
In term infants with an anatomical hemodynamically significant patent ductus arteriosus 
(hsPDA) intervention to close the duct is often indicated. The standardized procedure is to 
close the duct with percutaneous catheterization. This is done after a time of observation, and 
often when the child is up to 18-24 months of age or even older.46 
In extremely preterm born infants (<28 weeks) the recommendation to close the PDA 
pharmacologically has almost developed to become standard of care (even in infants born at 
28-32 weeks).8 Indomethacin and ibuprofen are cyclooxygenase (COX) inhibitors leading to 
a reduction of PG-mediated vasodilation in the ductal wall.7 The efficacy of these two drugs 
is comparable but the side effect profile is different as ibuprofen is believed to have less side-
effects on renal and mesenteric circulation.8,47 Paracetamol as a treatment for PDA has 
evolved recently. Moderate evidence suggest that it is as effective as ibuprofen.48 Studies in 
infants <28 weeks of age are lacking. Furthermore, concerns have been raised on prenatal and 
postnatal exposure to paracetamol and neurodevelopment and further studies are 
recommended.48  
In case of pharmacological treatment failure for hsPDA, surgical strategies are usually 
warrented. This has mostly been performed with an open thoracotomy, but video-assisted 
thoracoscopy techniques have evolved.9,49 It has been the general recommendation to close 
the PDA after prior pharmacological treatment in infants with a hsPDA.23 Primary PDA 
surgery has been a strategy but is no longer recommended, unless pharmacological treatment 
is contraindicated.9,23 These strategies have been subject to discussion in recent years. 
Percutaneous catheterization techniques for PDA closure have evolved as a treatment option 
recently. This technique is still in its research stadium for infants with very low birthweight 
(1000-1500g).9,46  
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Figure 2.2. Determinants of the flow through the duct. Printed with permission from 
©Elsevier. Ref. Smith et al. Seminars in Fetal and Neonatal Medicine. 2018.(23)245-249. 
2.4 DETERMINANTS OF THE FLOW THROUGH THE DUCT AFTER BIRTH 
Flow through vessels is determined by Poiseuille´s law as illustrated in Figure 2.2.50  
Resistance is dependent on the vessel radius, the length, and the viscosity of the blood that 
flows through the vessel.50 For the DA, the pulmonary and systemic pressures are the 
governing factors for the pressure difference and flow direction through the DA.6 
Furthermore, vasoconstriction and vasodilation of the DA change the radius.6 These 
constantly changing dynamics factors make estimation of the shunt through the duct difficult. 
• The postnatal decrease in pulmonary resistance results in changes of ductal flow from 
purely right to left in utero, to bidirectional during the transitional period, and purely 
left to right there after.6 
• In full term infants, smooth muscle cells in the ductal wall react to the oxygen tension 
changes postnatally, where higher oxygen tension triggers ductal closure.33  
Infants born extremely and very preterm are often very sick after birth and the postnatal 
transition can differ from full term infants. Here are a few examples of the dynamic nature of 
the flow through the duct in this group.  
• Directly after birth or during the first hours of life, many preterm infants develop 
respiratory distress syndrome and are treated with surfactant.  This has not only effect 
on the ventilation mechanics, but also on the pulmonary and systemic circulation.6,51 
As the lung opens and aerates, the pulmonary resistance decreases and the shunt, 
often bidirectional or right to left, changes to left to right through the duct.51   
• The ventilator strategy on invasive and non-invasive ventilation such as continuous 
positive airway pressure (CPAP) with the degree of positive end-expiratory pressure 
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(PEEP) can modulate the ductal shunt, i.e. higher PEEP decreases the shunt from left 
to right with increased pulmonary pressure.52 The shunt through the duct can be 
modified by changing the respiratory mode.6 
• Vasoactive mediators affect the ductal constriction.33 It has been described that in 
context with infections, the vasoactive inflammatory mediator; tumor necrosis factor 
alfa (TNF-alfa) is associated with delayed duct closure and even re-opening.53   
For the clinicians that care for the extremely preterm infants, the constantly changing 
“dynamic nature of the ductal shunt” due to these factors, becomes evident.  
When is the shunt through the duct of such a magnitude that it negatively impacts the infant?  
In approaching this, the definition of a hsPDA evolved.11,35 As shown in Figure 2.4 and 
described above, all infants are born with an open DA but not all develop pathological 
symptoms related to it. It has been intensively debated which predictors are most relevant of a 
significant ductal shunt in the population of extremely preterm infants. Clinical signs have 
been shown to evolve late, when the infant has already developed a significant shunt.54 The 
role of echocardiography as a diagnostic tool in confirming non-closure of the duct and 
staging the ductal severity has been shown to be of importance. Echocardiographic markers 
are as a proxy of the ductal flow and shunt magnitude but do not always account for the 
dynamic changes.6,55  
2.5 ECHOCARDIOGRAPHIC DIAGNOSTICS OF THE PDA 
 
Figure 2.3. Ductal view on two dimensional echocardiography and color Doppler. 
©Anna Gudmundsdottir. 
Echocardiography remains the golden standard for confirming the presence of a PDA.56  
Furthermore, by using echocardiographic surrogate markers, it is possible to estimate the 
excessive pulmonary circulation and systemic hypoperfusion due to the ductal shunt.35,55 In 
Table 2.1 the most common echocardiography markers and the method used to acquire them 
are detailed. This is the base for the definition of the echocardiographically significant PDA, 
i.e. a moderate to large duct with significant signs of shunt and increased left ventricular 
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output.35 With more advanced echocardiography, further estimations of left ventricular output 
and myocardial performance are possible.57 
The markers can be categorized into ductal size and flow characteristics, signs of excessive 
pulmonary circulation and systemic hypoperfusion (end-organ steal), as well as heart function 
and size of left atrium and ventricle.35,55,58-63  The studies underlying these criteria are mostly 
from the first week of life in extremely and very preterm infants (born at less than 30-32 
weeks of gestation). In a newly published study, the conventional echocardiographic PDA 
markers only showed a fair correlation with a significant ductal shunt at more than 7 days of 
age so further investigation is needed.64  
In Table 2.1 the most common echocardiographic markers are described 
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Table 2.1. Commonly used echocardiographic markers for hemodynamic significant PDA (hsPDA) 
 Echocardiographic criteria and cut-off values Echocardiographic projection Ref. 
Ductal characteristics 
Diameter Diameter of the duct (>1.5mm)  Ductal diameter acquired with two dimensional (2D) mode at the narrowest diameter of 
the ductal pulmonal end, in high parasternal short axis (ductal view) 
35,59 
Direction of flow 
through duct 
Left to right shunt (L->R) Colour Doppler (CD) used to detect the PDA and the direction of the flow (L->R, 
bidirectional or R->L) 
35,58 
Flow 
characteristics 
Pulsatile flow through the duct with a non-
restrictive flow profile 
Duct visualized from ductal view. Velocity through duct measured either with Pulsed 
Wave Doppler (PWD) or Continuous Wave Doppler (CWD) 
35,58 
Excessive pulmonary flow 
Left atrium Left atrial to Aortic root (La:Ao) ratio ( >1.5)  Left atrial diameter determined in 2D-mode according to guidelines and standards in a 
parasternal long axis view  
55,61 
Pulmonary flow 
characteristics 
End-diastolic flow in LPA/RPA (>0.2m/s)  Diastolic forward flow (velocity) with PWD in RPA and LPA from a high parasternal 
short axis view 
35,55 
Mitral valve 
function 
Mitral valve early phase to atrial phase velocity 
ratio (E:A)  (≥1 signifies increased pulmonary 
venous return and left atrial pressure loading) 
Colour Doppler and PWD obtained in apical view.  35 
End-organ ductal steal 
Ductal steal signs Reversed diastolic flow in descending aorta 
/reversed or absent flow in mesenteric artery and/or 
cerebral arteries (ACA, MCA) 
PWD used to detect reversed diastolic flow in descending thoracic aorta and images 
acquired from a high parasternal view. The subcostal view used for abdominal aorta or 
mesenteric diastolic reversed or absent flow.  PWD from cerebral arteries (ACA) 
assessed for reversed or absent diastolic flow. 
35,65 
Heart failure and ventricular enlargement 
Left ventricle Signs of enlargement  Left ventricle diameter was determined in 2D-mode according to guidelines and 
standards in a parasternal long axis view 
62 
Cardiac output Left ventricle output (LVO) 
= Stroke volume (SV) x heart rate/minute 
If >300ml/kg/min considered significant 
Measured in apical 4 chamber view and parasternal long axis view.  
SV = 𝜋 x AoV annulus2/4 x VTI LVOT (AoValve annulus hinge point).   
35 
Abbreviations: hsPDA: hemodynamically significant Patent Ductus Arteriosus, 2D: Two dimensional, La: Left Atrial, Ao: Aorta root, LPA: left pulmonary artery, RPA: right 
pulmonary artery, PWD: pulse wave Doppler, CWD: continuous wave Doppler, ACA: anterior cerebral artery; MCA: middle cerebral artery. LVO: left ventricle output, VTI: 
Velocity time integral. AoV: Aorta Valve Annulus.  LVOT: Left ventricular outflow tract.  
 10 
2.6 CLINICAL DIAGNOSTICS OF THE PDA 
Signs of a significant PDA are not always evident during the first days but appear later.  In 
the definition proposed by McNamara and Sehgal in 2007 a hemodynamic significant PDA 
fulfills both echocardiographic and clinical criteria.35  The problem is that the symptoms may 
differ depending on the infant´s age, i.e. not being the same during the first 24 hours of life, at 
3 days of age or at >7 days of age. In Table 2.2, the clinical criteria most often used are 
detailed.  
Table 2.2. Clinical signs of a hemodynamic significant Patent 
Ductus Arteriosus (hsPDA) 
 Comment 
Heart murmur  
Bounding femoral pulses Non-specific  
Number of apneas and 
bradycardias 
Non-specific 
Need for respiratory support, 
failed extubation 
Both invasive (ventilator) and 
non-invasive (CPAP, nasal 
cannula) 
Fraction of inspired oxygen (FiO2) No specific cut off limits.  For 
PDA surgery 
Signs of pulmonary congestion on 
X-ray 
Need of diuretics 
Circulatory failure Hypotension, need of inotropes 
Feeding intolerance Proportion of enteral to parenteral 
nutrition 
Renal failure, oliguria Creatinin and urea value, diuresis 
in mL/kg/day or hour 
Ref. 7,35,66 
 
2.7 BIOMARKERS AS DIAGNOSTIC TOOLS FOR PDA 
Recently, cardiac biomarkers have been investigated and proposed as complementary tools in 
PDA diagnostics.67,68 The biomarkers of most interest are N-Terminal fragment-pro-Brain 
Natriuretic Peptide (NT-proBNP) and cardiac Troponin T (cTnT).68In adult and pediatric 
cardiology, they are used to evaluate heart failure and myocyte injury, such as in myocardial 
infarction.69-71 The most well-studied biomarkers are the peptide NT-proBNP which is 
biologically inactive which is secreted together with the biologically active natriuretic peptide 
BNP.67 They are released in response to ventricular and atrial wall stretching and used 
generally as67 markers of congestive heart failure. Of particular interest is how BNP is used in 
determining the effect of mitral regurgitation on left ventricular dysfunction and predicting 
symptom onset.72 This in some ways resembles how the effects of the left to right shunt 
through the duct affects the left ventricle and atrium in infants with a hemodynamically 
significant shunt.73 NT-proBNP is the biomarker preferably used. In term healthy infants, 
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NT-pro-BNP has been shown to rise during the transition period after birth, peaking in the 
first 48 hours and then decreasing the following days.74 
cTnT is a protein in the cardiac muscle that is secreted in response to myocyte injury.67 It has 
been associated with respiratory disease morbidity (pulmonary hypertension, RDS) and 
circulatory failure in infants, caused by for example PDA, both in term and preterm 
infants.75,76 It is used as a marker of perinatal asphyxia in term infants.77 It has been 
postulated that the correlation between PDA and cTnT levels stems from myocardial 
ischemia due to the ductal steal of blood flow affecting the coronary arteries especially in 
preterm infants.78  
Both NT-proBNP and cTnT have been associated with myocardial function in the preterm 
population and correlated with echocardiographic markers.76 The analysis methods are based 
on immunochemistry methods and are in general the same for cTnT between laboratories, but 
not for NT-proBNP where the analysis may differ between laboratories.67,68  
The use of biomarkers as a complement to scoring systems is an attractive approach, as they 
are neither dependent on echocardiographic resources, nor associated with inter-examiner 
variability.  Studies on NT-proBNP values in infants with hsPDA have detected associations 
with PDA treatment or not as well as decreased values after treatment.79,80 As the 
immunochemistry assay methods for NT-proBNP can differ between laboratories, it has been 
difficult to compare the levels in different studies in infants with a hsPDA.67  Furthermore, 
few of these studies have included the most immature infants, born at ≤ 25 gestational weeks, 
although these infants have the most complex hsPDA.67  Higher levels of NT-proBNP have 
also been correlated to BPD.81 However, these studies suffer from the lack of consistent 
definitions of hsPDA, as well as the variation in laboratory methods used.67,68  
Interestingly, NT-pro-BNP and cTnT have been shown to predict both short term adverse 
outcome (IVH grade 2 or higher /cPVL or death) and neurological outcome at two years of 
age in preterm infants with PDA in the neonatal period.82
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2.8 PATHOPHYSIOLOGIC CONSEQUENCES OF THE DUCTAL SHUNT AND 
RELATION TO OUTCOMES 
 
Figure 2.4. The physiological effects of the shunt on the preterm circulation are shown 
and where the potential treatment strategies are applied. Printed with permission from M. 
Kluckow and ©Elsevier. From Hemodynamics and Cardiology Elsevier series. Editors I. Seri 
and M. Kluckow. 2018 Fig 25.3 in Ch 25.  
The changes after birth and during the transition with the decrease in pulmonary pressure and 
the changes from bidirectional to mainly left to right shunt are shown in Figure 2.4. In 
extremely preterm infants, already during the first day the shunt is mainly left to right. The 
hemodynamic effects are an excessive flow (hyperperfusion) in the pulmonary circulation 
and hypoperfusion in the brain and systemic circulation with risk for pulmonary hemorrhages 
and IVH’s respectively.6  Furthermore, the ductal shunt is a factor in the hypotension often 
seen in extremely preterm infants during the first 24-48 hours though the abrupt stop for 
placental flow is probably the main factor.6  
Later, with unlimited left to right shunt through the duct, as a result, reversed flow (steal) may 
occur in the systemic circulation both in the mesenteric and brain circulation, both theoretical 
risk factors for NEC and PVL respectively.6 The excessive lung flow has been associated 
with the risk of BPD.6,83 
2.9 PDA TREATMENT STRATEGIES IN CONTEXT WITH DUCTUS 
PHYSIOLOGY 
It is debated how the treatment strategies are associated with the outcomes, and which 
strategies prevent (if possible at all) the outcomes of interest. The neonatal morbidities most 
studied in association with PDA are: IVH, pulmonary hemorrhage, necrotizing enterocolitis 
(NEC) and BPD. Later neurodevelopmental outcome is always a concern in the extremely 
preterm population and the association with such a common exposure as PDA is important. 
Prophylactic treatment (without an echocardiography) with indomethacin was applied but as 
it has not been shown to have long-term benefits it is generally not applied.84 
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• Early targeted treatment, where an early echocardiography is performed to confirm a 
PDA) has been applied in Australia and has been shown to reduce pulmonary 
hemorrhages.85  
• Pre-symptomatic treatment before 72 hours of age, where echocardiographic 
classification is the cornerstone of the selection of infants for treatment. This is 
probably the most commonly applied strategy the past years.7 
• Late symptomatic start of treatment, at about one week of age or later has been 
gaining more interest.7 The questions have been raised if the defined 
echocardiographic criteria are adapted to this strategy.11,64   
• Surgical treatment is reserved for infants not responding to pharmacological treatment 
or having contraindications to it. It is most often performed at a few weeks of age (3-6 
weeks)9   
• Conservative treatment, with nasal CPAP, diuretics and volume restriction is widely 
practiced but so are far not fully evaluated.50   
2.10 PDA AS AN EXPOSURE AND ASSOCIATED OUTCOMES 
In a paper by Zonnenberg et al the diagnostics underlying the PDA exposure in trials are 
discussed.86 Wide variation was found, as some are based solely on clinical symptoms (for 
example heart murmur), others on echocardiographic markers and still more have a 
comprehensive approach with the combination of echocardiographic markers and clinical 
signs.86 The diagnosis is the underlying factor for the decision to treat, which is the most 
common PDA exposure used.  
In many randomized-trials and cohort studies on PDA in the preterm population, the exposure 
is defined as PDA treatment or not (yes/no). This dichotomized exposure does not account 
for the ductal severity, which is more of a spectrum. Most studies do have information on 
PDA treatment categories, pharmacological with or without PDA surgery, but very few until 
now have information on conservative treatment of the PDA.   
The “true” incidence of PDA in the very and extremely preterm population is yet to be 
established. Publications on the spontaneous PDA closure rate in very and extremely preterm 
infants are appearing.30-32 In a European cohort study, with low rates of PDA treatment, the 
median time to ductal closure varied from 6 days in infants born at ≥30 weeks GA, 8 and 13 
days for infants born at 26-30 weeks to 71 days for infants born at <26 weeks.29  
The incidence of PDA treatment in the very and extremely preterm population has been 
changing the past 15 years. In the EXPRESS Swedish cohort study, 61% of the infants born 
at <27 weeks of gestation were treated for PDA, either pharmacologically with or without 
later surgery or primary PDA surgery.4 Similar treatment rates from Europe, North-America 
and Japan have been described for the same period.3,87-89 Many studies have reported 
variation and changes over time in treatment strategies. The NICHD Neonatal Research 
Network in the USA has described variation between participating centers in PDA diagnosis 
and all types of PDA treatment during the years 2003-2007.3 There was three and four-fold 
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variation in pharmacological PDA treatment and PDA surgery respectively during this 
period.3 From the Canadian Neonatal network declining rates of PDA treatment have been 
reported between 2012 and 2016.90 This is confirmed by Bixler et al where changes in PDA 
treatment strategies over time in the US from 2006 to 2015.5 The most pronounced changes 
have been in the PDA surgery strategy, with rates falling from 8.4% to 2.9%.5 Further 
analyses of associations with morbidities was not described in detail.5 
PDA surgery strategies are controversial, as it is a complicated procedure in a vulnerable 
population. Strategies have varied from early surgery after failed pharmacological treatment 
to later surgery after a long observational period of the infant. Prophylactic and early surgery 
at <10 days of age have been associated with poor outcomes, such as BPD and adverse 
neurodevelopment.91-94 The clinical discussion now is focused on selecting the right infants 
for surgery. Standardization, and a system for categorizing and triaging infants in a referral 
center in Toronto Canada resulted in improved outcomes after PDA surgery.95 
PDA and association to neonatal mortality and morbidities 
A causal relationship has not been confirmed between PDA or hsPDA and short- and long-
term outcomes. The following outcomes will be discussed:  mortality, IVH, pulmonary 
hemorrhage, NEC, BPD and neurodevelopmental outcome.  
Mortality  
Survival after extremely preterm birth has increased the past decades. In the EXPRESS 2004 
to 2007 cohort of infants born at <27 gestational weeks, one-year survival among live-born 
infants was 70%.13 In a newly published article from the same group, the survival has 
increased to 77% in a population based Swedish cohort from 2014-2016.1 Similar reports are 
published from other countries.2,3 Survival is strongly associated with gestational age (GA) as 
earlier reported.13 Infants having a hsPDA on day 3 have been shown to have increased risk 
of later mortality.96,97 As mortality is highest in extremely and very preterm infants during the 
first week, it has to be accounted for when examining PDA outcomes in this group.98  
IVH 
The association of significant ductal steal shortly after birth followed by brain hypoperfusion, 
with risk of IVH is known.6,99
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Pulmonary hemorrhage 
In a randomized trial of early targeted PDA treatment, where an early echocardiography is 
performed to confirm a PDA there was a decrease in pulmonary hemorrhages in the group 
receiving early PDA treatment with indomethacin.85 
NEC 
Theoretically the ductal steal leads to ischemia in the gut of infants with a hsPDA.  The 
association of PDA and later NEC has not been easy to study, but an association has been 
described.100,101 
Bronchopulmonary dysplasia (BPD)  
BPD is most commonly defined in PDA studes as oxygen need at 36 weeks postmenstrual 
age (PMA).102 Previous studies have suggested that early PDA treatment leading to PDA 
closure is beneficial in terms of decreased pulmonary morbidity and development of 
BPD.103,104 It is still unclear if there is a causal relationship between PDA and BPD. In a 
randomized trial of early versus later ibuprofen treatment, Sosenko et al. did not find any 
differences in BPD incidence or mortality between the two groups.105 Moreover, in the Trial 
of Indomethacin Prophylaxis in Preterm infants, indomethacin prophylaxis reduced the 
incidence of PDA, but did not change the BPD incidence93.  PDA surgery has often been 
associated with BPD, but in the same manner, it has been complicated to disentangle the 
association.83  
Neurodevelopmental outcome  
Various cohort studies have shown an association between PDA treatment and later adverse 
neurodevelopmental outcome.24,25,27 PDA surgery, especially, has been associated with 
adverse neurodevelopmental outcome but this is constantly debated.98 Neurodevelopmental 
outcomes are most often determined with Neurodevelopmental Impairment (NDI) as defined 
by Moore et al.16 NDI is categorized into none, mild, moderate or severe and includes hearing 
impairment, visual impairment, presence of cerebral palsy (as defined by Gross Motor 
Function Classification System) and cognitive assessment according to the appropriate test 
for age.16 A common age to investigate neurodevelopmental outcome is 18-24 months using 
Bayley Scales of Infant Development.106 Evaluation of cognitive development is more 
comprehensive at school-age compared to two years of age. Assessment with for example 
Wecshler Scales of Child Development (WISC) at 6.5 years of age is often used.17 The 
overall results are presented as full-scale intelligent quotient (FSIQ) and usually compared 
with a standard population or matched controls (distribution of the mean and standard 
deviations).  
2.11 EPIDEMIOLOGICAL CONCERNS IN PDA STUDIES 
Epidemiologic terminology of importance for the studies on PDA in this thesis. 
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1. Confounding:  As defined by Rothman is a mixing of effects that is most often 
imbalanced between the the groups being compared (exposed and non-exposed).107 A 
confounder must be associated with the disease but may not be an effect of the 
disease.  A confounder must also be associated with the exposure.107 
2. Bias: A systemic error in studies is called bias. It can be introduced when designing 
the study, by choosing the measurement for the outcome or if a confounding factor is 
not completely controlled for.107 
 
 
Figure 2.5. In this flow chart possible clinical outcomes in an extremely preterm infant 
developing a hsPDA are shown and where multiple factors can introduce bias.  
Causality has not been confirmed in any studies of PDA and outcome, but associations 
have been detected.  Possible timepoints for intervention and modifying disease are 
noted as well as possible methods to handle bias in future studies on PDA. Published 
with permission from ©Elsevier. Ref. El-Khuffash et al. Arch Dis Child Fetal Neonatal Ed. 
2016.101(5):F474-8. 
Abbreviations: hsPDA: hemodynamically significant patent ductus arteriosus. pPROM: preterm premature 
rupture of the membranes. PET: pre-eclampsia. TnECHO: targeted neonatal echocardiography. IVH: 
intraventricular hemorrhage, NEC: necrotizing enterocolitis. BPD: bronchopulmonary dysplasia.  
In Figure 2.5 by El-Khuffash et al.108, epidemiologic factors associated with PDA are 
explained.  In preterm infants, mainly extremely preterm infants the best way to study PDA 
as an exposure is to use predefined echocardiographically and clinical criteria of when it is 
pathological.11,108  In many published studies as well as the studies in this thesis the exposure 
is PDA treatment and the exact criteria for treatment are not always clear. It is important to 
have a well characterized cohort with optimal, predefined perinatal and early neonatal data as 
well as the temporal relation to morbidities such as sepsis.28  This is important when 
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understanding the associations with the outcomes measured. Possible entries of bias are 
many. Selection bias, which can be handled with randomized trials or by restricting the 
studies to the population most representative for PDA problems (i.e. <26-28 weeks).107,108   
Measurement bias is for example when ductal significance is measured using different 
criteria. This leads to heterogeneity in the classification and can be called a misclassification 
bias.109 Bias due to confounding can be handled with thourough data collection of potential 
confounders and in selecting appropriate statistical analyses.107,108 Lastly, choosing the 
appropriate outcomes and the best method to measure them are equally important.108  
Following is an example of the PDA exposure and the outcome in question in paper III where 
possible covariates and confounders are illustrated. 
Example  
 
Figure 2.7.  PDA surgery and association with FSIQ at 6.5 years of age as measured 
by WISC IV17.   
Abbreviations: GA: gestational age. SDS: standard deviation score. BWT: birth weight PDA:  patent ductus 
arteriosus. IVH: intraventricular hemorrhage.  BPD: bronchopulmonary dysplasia. NEC: necrotizing 
enterocolitis. FSIQ: full-scale intelligent quotient: WISC-IV: Wechsler intelligence scale for children, 
version IV. 
As shown in Figure 2.7 there are many possible covariates, which are related to the 
exposure or the outcome.  Some are true confounders, as they are related to both the 
exposure and the outcome as shown. GA is strongly associated with both the need of 
PDA treatment and neurodevelopmental outcome.15 Presence of IVH is also of 
importance as it is related to both GA and risk of primary PDA surgery (IVH is a 
contraindication for NSAID treatment of PDA) as well as neurodevelopmental 
outcome.110 This is an example, other associations than those illustrated are possible. 
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3 AIMS AND RESEARCH QUESTIONS 
The aim of this thesis is to explore the incidence and type of PDA treatment and the 
association with short- and long-term outcome in extremely preterm infants. Furthermore, 
the aim is to study the role of cardiac biomarkers in assessing PDA severity in extremely 
preterm infants. 
The research questions are: 
1) Is age at start of PDA treatment with Non-Steroidal Anti-Inflammatory Drugs 
(NSAID´s) associated with later risk of surgical closure of the PDA or death before 3 
months of age; or with later risk of BPD in infants surviving to 36 weeks post-menstrual 
age? (Paper I) 
2) How does PDA treatment vary after very preterm birth in Europe, and are different 
approaches to PDA treatment associated with BPD or survival without major morbidity 
after very preterm birth? (Paper II) 
3) Is the type and timing of PDA treatment (e.g. surgery, pharmacological or both) 
associated with neurodevelopmental outcome at early school-age in children born 
extremely preterm?  (Paper III) 
4) How are the cardiac biomarkers Troponin T and NT-proBNP correlated to different 
PDA treatment types of an echocardiographically hsPDA in extremely preterm infants? 
(Paper IV) 
5) What is the probability of spontaneous PDA closure in extremely preterm infants and 
are the cardiac biomarkers helpful in predicting spontaneous closure? (Paper IV) 
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4 MATERIALS AND METHODS 
4.1 OVERVIEW OF THE STUDIES 
 
 Study I Study II Study III Study IV 
Design Prospective 
cohort study 
Prospective 
cohort study 
Prospective 
cohort study 
Prospective cohort 
study 
Population EXPRESS 
cohort 
All infants born 
in Sweden 
EPICE cohort 
Infants born in 
19 regions in 11 
countries in 
Europe 
EXPRESS 
cohort 
All infants born 
in Sweden 
DEDUCT cohort  
Level III county 
hospital. Inborn at the 
Karolinska University 
Hospital, Stockholm 
Gestation 
weeks 
<27 weeks of 
gestation 
<32 weeks of 
gestation 
<27 weeks of 
gestation 
<28 weeks of 
gestation 
Number of 
infants 
included 
290 6896 435 98 
Study 
period  
2004-2007 2011-2012 2004-2007  2012-2014 
Exposure Timing of 
NSAID 
pharmacological 
PDA treatment 
PDA treatment, 
pharmacological 
and/or surgical 
PDA treatment 
(pharmacological 
and/or surgical), 
both mode and 
timing 
Presence of an 
echocardiographically 
verified hsPDA 
Outcome a. PDA surgery 
or death 
b. BPD in 
survivors at 36 
weeks PMA 
BPD or death at 
36 weeks PMA.  
Survival without 
major neonatal 
morbidities 
(IVH≥3, PVL, 
surgical NEC, 
ROP≥3) 
NDI and FSIQ at 
6.5 years of age 
PDA closure: 
spontaneous, after 
ibuprofen treatment 
or with PDAsurgery  
Follow-up 
time 
a. 90 days of age  
b. 36 weeks 
PMA  
36 weeks PMA 6.5 years of age 40 weeks PMA 
Main 
research 
question 
Timing of PDA 
treatment and 
association with 
death, need of 
PDA surgery 
and BPD at 36 
weeks of age. 
Variation of 
PDA treatment 
and association 
with outcomes at 
36 weeks PMA. 
Mode and timing 
of PDA 
treatment and 
association to 
cognitive 
outcomes at 6.5 
years of age. 
Association of 
gestational age with 
PDA closure. 
Association of 
markers of ductal 
severity to treatment.  
Association of 
markers of ductal 
severity with PDA 
closure. 
4.1.1 Papers I and III 
Study design   
In papers I and III, infants were born at less than 27 weeks of gestation in Sweden from April 
1st 2004 to March 31st 2007 and included in a prospective national population-based cohort 
(EXPRESS).13 The main purpose of the EXPRESS cohort study was to explore factors of 
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significance for survival and morbidity after extremely preterm birth.13 Inclusion criteria for 
the studies in papers I and III are displayed in Figure 4.1.1.1 
 
Figure 4.1.1.1 Flow chart of inclusion for studies in paper I and paper III. Exclusion 
criteria, missing data and lost due to follow-up is detailed. 
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Data collection 
Data in the EXPRESS study was collected from all of the 42 delivery departments where the 
infants were born. Of all included infants, 82% were born at the 7 regional level III hospitals 
in Sweden, as the intention has been to centralize extremely preterm deliveries to these 
hospitals. The data was acquired at each local hospital prospectively from mother´s and 
infant´s medical charts. Data was collected on demographic information, maternal pregnancy 
factors, birth and resuscitation, selected procedures in the neonatal unit, common exposures 
and outcomes of the extremely preterm infant. All data was collected on standardized study 
forms in accordance with a manual defining the variables. Regional data was then 
electronically transferred to a central database, in collaboration with the Swedish Perinatal 
Quality Register (MedSciNet AB, Stockholm, Sweden). Data on live-born infants, admitted 
to the neonatal department, was collected prospectively until discharge, even if the infant was 
transferred to another hospital or till death occurred. Quality controls were conducted, both 
for missing or erroneous data, and internal and external validity was checked.13 
In the EXPRESS cohort, PDA was defined as pharmacologically treated, surgically treated or 
both. PDA was diagnosed with echocardiography, but the details of the ductal 
echocardiographic severity were not collected.111 Infants having a conservatively treated PDA 
were not defined as having a PDA in the study. The exposures, outcomes and statistical 
methods for papers I and III are shown in Table 4.1.1.1 and 4.1.1.2 
Table 4.1.1.1 Exposures, outcomes and analysis methods used in Paper I 
Exposure Outcome Analysis method* 
Timing of pharmacological PDA 
treatment categorized (according 
to tertiles of distribution) into:  
-0-2 days of age (reference) 
-3-6 days of age 
-≥7 days of age 
A composite outcome of PDA 
surgery or death 
 
 
 
 
 
 
 
 
BPD at 36 weeks postmenstrual 
age in surviving infants  
COX regression analysis with 
stratification on gestational age 
and hazard ratio (HR). Follow-up 
time was from start of 
pharmacological treatment  
and up to 90 days of age, date of 
PDA surgery or death, whichever 
occurred first.  
 
Logistic regression analysis, 
(Odds ratio, OR) stratified on 
gestational age and  
adjusted for sex, SGA status and 
duration of mechanical 
ventilation. 
*To take intra-regional correlation between observations into account, the cluster statement in STATA was used in 
the regression models. Introducing the cluster statement into the regression model does not change the point 
estimate of the hazard ratio but influences the standard error. 
Abbreviations: PDA: patent ductus arteriosus. BPD: bronchopulmonary dysplasia. SGA: Small for gestational 
age (>-2SD below the mean birthweight). 
 24 
Table 4.1.1.2 Exposures, outcomes and analysis methods used in paper III.  
Exposure Outcomes Analysis method* 
Type of PDA treatment 
-NSAID treatment 
-PDA surgery after prior NSAID 
treatment 
-Primary PDA surgery  
Neurodevelopmental Impairment 
(NDI) categorized into: no or mild 
and moderate or severe NDIa 
 
 
 
Full-Scale Intelligence Quotientb 
(FSIQ) as a continuous variable. 
A mixed-effects regression 
modified Poisson model, 
presented as incidence rate ratios 
(IRR) with [95% confidence 
intervals (CI)]. Adjustments made 
for GA, sex, birthweight, SDS 
birthweight, IVH grades 3 or 
higher and maternal education.  
In a mixed-effects generalized 
linear regression model and 
presented as adjusted mean 
difference in FSIQ with with 
[95% confidence intervals (CI)] 
Adjustments made for GA, sex, 
birthweight, SDS birthweight, 
IVH grades 3 or higher and 
maternal education. 
Timing of PDA treatment 
categorized as:  
Pharmacological:  
-0-2 days of age (reference) 
-3-6 days of age 
-≥7 days of age   
 
Surgical:  
-≤10 days of age 
-11-20 days of age 
->20 days of age (reference) 
Neurodevelopmental Impairment 
(NDI) categorized into: “no or 
mild” and “moderate or severe” 
 
 
 
 
Full-Scale Intelligence Quotient 
(FSIQ) as a continuous variable 
A mixed-effects regression 
modified Poisson model, 
presented as incidence rate ratios 
(IRR) with [95% confidence 
intervals (CI)]. Adjustments made 
for GA, sex, birthweight, SDS 
birthweight, IVH grades 3 or 
higher and maternal education. 
 
In a mixed-effects generalized 
linear regression model and 
presented as adjusted mean 
difference in FSIQ with with 
[95% confidence intervals (CI)]. 
Adjustments made for GA, sex, 
birthweight, SDS birthweight, 
IVH grades 3 or higher and 
maternal education. 
* To account for potential clustering, the models included region and mother as the random effect variables 
except in the model investigating the association of timing of PDA treatment and FSIQ, where only region 
was included because of limitations in power.  
aNeurodevelopmental Impairment as defined according to Moore et al 2012. 16 
bFull-Scale Intelligent quotient (FSIQ) as determined by Wechsler Intelligence Scale for Children (WISC-IV) 
results.17 
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4.1.2 Paper II 
Study design  
In paper II, the Effective Perinatal Intensive Care in Europe (EPICE) Cohort Study was a 
prospective European cohort study, including 19 regions in 11 countries in Europe. It was 
conducted during a 6 to 12 months period (depending on region) in very preterm infants 
(born at <32 gestational weeks) from 2011-2012. Included in paper II were a total of 6896 
infants, all surviving to ≥24 hours of age.14 A flow chart of the study is shown in Figure 
4.1.2.1 
 
Figure 4.1.2.1 Flow chart of inclusion for the study in paper II. Exclusion (death before 
24 hours of age) and missing data are detailed. © 2017 S. Karger AG, Basel. Published 
with permission. 
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Data collection  
In all regions, information on type of PDA treatment and date of start of treatment were 
collected. The diagnosis of PDA differed between regions but was based on a clinical and/or 
echocardiographic assessment. Echocardiographic PDA diagnosis was available on site for 
6768 infants (98.1%). Data was collected about each infant until death or hospital discharge. 
The exposures, outcomes and statistical analysis methods are shown in Table 4.1.3.1. 
Table 4.1.2.1. Exposures, outcomes and statistical analysis methods used in Paper II.  
Exposure Outcome Statistical analysis method** 
PDA treatment: 
-NSAID (ibuprofen or 
indomethacin) treatment 
-PDA surgery after prior NSAID 
treatment 
-Primary PDA surgery 
Composite outcome of BPD or 
death before 36 weeks gestationa 
 
 
 
 
 
 
 
Survival without major neonatal 
morbidityb  
Mixed-effects generalized linear 
regression models presented as 
risk ratios (RR) with [95% 
confidence intervals (CI)]. 
Adjustments for gestational age 
(GA) separately and then for the 
propensity score* (which included 
GA). 
 
As above with further adjustments 
for total duration of mechanical 
ventilation and number of 
confirmed septicemias.   
*Propensity score for PDA treatment: A single index variable which summarizes the pre-treatment perinatal 
characteristics. It was estimated from presence of preeclampsia/eclampsia, spontaneous onset of labor, 
preterm premature rupture of membranes (pPROM), maternal infection as indication for delivery, antenatal 
corticosteroid treatment, mode of delivery, gestational age, birth weight, infant sex, small for gestational age 
(>-2SD below the meanbirth weight) and use of mechanical ventilation on first day of life. 
**Clustering: It was accounted for in the analyses, where the neonatal unit was added as the random effects 
variable in the multi-level mixed effects model. In a separate analysis, the identity of the mother was added as 
a second random effect, as multiples could have more similarities.  
aBronchopulmonary dysplasia (BPD) defined as any oxygen treatment at 36 weeks postmenstrual age (PMA) 
bMajor neonatal morbidity defined as presence of any of the following: intraventricular hemorrhage (IVH) 
grade ≥ 3, cystic periventricular leukomalacia (cPVL), necrotizing enterocolitis (NEC) requiring surgery or 
peritoneal drainage, or retinopathy of prematurity (ROP) stage≥ 3 
4.1.3 Paper IV 
Study design  
In paper IV, a prospective hospital-based cohort study was conducted at the neonatal 
intensive care unit at the Karolinska University Hospital Solna, from February 14th 2012 to 
July 31st 2014. All infants born at this hospital at less than 28 weeks gestational weeks and 
admitted to the NICU were eligible for inclusion. A flow chart of the inclusion criteria is 
shown in Figure 4.1.3.1. Reasons for non-inclusion were cardiac or other major 
malformation, death before 72 hours, critically ill infants or mothers during the first 72 hours 
and non-availability of study personnel. Ninety-eight infants were included in the final 
analysis.   
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Figure 4.1.3.1 Flow chart of inclusion and exclusion critera for the study in paper IV.
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Study protocol 
Echocardiography was performed for all infants on day 3, day 7, and day 14 (for infants not 
treated), before PDA treatment and following PDA treatment. Neonatologists trained in 
echocardiography performed the echocardiography according to a clinical protocol shown in 
Table 4.1.3.1.  The cardiac biomarkers NT-proBNP and cTnT were measured in blood 
samples collected in 0.5 ml lithium heparin tubes and analysed at the Karolinska University 
Hospital Accredited Laboratory. The results were registered in the electronic medical record, 
so the neonatologist in charge of the infant was not blinded to the results.  The timepoints 
chosen for further analyses of the echocardiography and cardiac biomarker measurement 
wereday 3 and day 7. The predefined age ranges accepted for the day 3 measurement was 2-4 
days, and 5-9 days for the day 7 measurement. 
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Table 4.1.3.1. Clinical local guidelines for hemodynamic Patent ductus arteriosus (hsPDA) at the Karolinska University Hospital during 2012-
2014  
• The PDA treatment decision was at the discretion of the neonatologist in charge.  
• Local guidelines for PDA treatment combined echocardiographic and clinical criteria. 
• Clinical criteria were: respiratory failure, FiO2, cardiorespiratory instability and signs of heart congestion on x-ray, signs of kidney failure and 
feeding difficulties. 
• The echocardiography was Neonatologist Performed Echocardiography (NPE) according to a revised clinical study protocol.  
 Echocardiographic criteria (at least the ductal characteristics and one other had to be present) 
Ductal characteristics 
Diameter Diameter of the duct >1.5mm  
 
Direction of flow through 
the duct 
Left to right shunt 
(L->R) 
Flow characteristics Pulsatile flow through the duct with a non-restrictive flow profile 
Excessive pulmonary flow 
Left atrium Left Atrial to Aortic root (La:Ao) ratio >1.5  
 
Pulmonary flow 
characteristics 
End-diastolic flow in LPA/RPA >0.2m/s  
 
End-organ ductal steal 
 Signs of ductal steal (reversed diastolic flow in descending aorta /reversed or absent flow in mesenteric artery and/or 
cerebral arteries (ACA) 
 
Heart failure and ventricular enlargement 
 Visual signs of left ventricular enlargement (Left ventricle end-diastolic diameter was not routinely measured) 
Abbreviations: hsPDA: hemodynamically significant Patent Ductus Arteriosus, 2D: Two dimensional, La: Left Atrial, Ao: Aorta, LPA: left pulmonary 
artery, RPA: right pulmonary artery, PWD: pulse wave doppler, CWD: continuous wave doppler, ACA: anterior cerebral artery  
References: 35,55,58,59,62 
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Data collection 
Data on perinatal and neonatal characteristics as well as the results of the biomarker 
measurements were extracted from the infants’ medical charts. Ultrasound studies were 
evaluated off-line for PDA related measurements by the study investigators according to a 
predefined protocol. If an echocardiographic image was missing for the evaluation, results 
from the medical chart were used to replace that measurement. For a complete description of 
all materials (ultrasound equipment and cardiac biomarker measurements), see manuscript 
paper IV. 
The exposures, outcomes and statistical methods for study 4 are shown in Table 4.1.3.2 
Table 4.1.3.2. Exposures, predictors and outcome and analysis method used in paper IV. 
Exposure Outcome Statistical analysis method 
Presence of an 
echocardiographically determined 
PDA 
-all infants in cohort 
-categorized into infants born at 
<25 weeks or ≥25 weeks 
-categorized according to 
treatment strategies  
PDA closure (confirmed with 
echocardiography, defined as no 
flow through duct with color 
Doppler on ultrasound). 
Survival curves (Kaplan-Meier) 
were used to describe the 
incidence of ductal closure over 
time, from birth to 40 weeks 
postmenstrual age (PMA).  Infants 
were censored at death, transfer to 
hospital out of county or surgical 
closure of the PDA, whichever 
occurred first.  
Presence of an 
echocardiographically determined 
PDA and infants categorized into 
born at gestational age <25 weeks 
or ≥25 weeks 
PDA closure (confirmed with 
echocardiography, defined as no 
flow through duct with color 
Doppler on ultrasound). 
As above. To compare Kaplan-
Maier curves, the χ2 method using 
Log-rank and Wilcoxon non-
parametric tests were performed. 
Presence of an 
echocardiographically confirmed 
PDA and associated NT-proBNP 
and cTnT value on day 3 and day 
7. 
PDA treatment categories: 
-spontaneous closure≤7 days 
-no PDA treatment  
-only ibuprofen PDA treatment 
-all PDA surgery 
Descriptive statistics with median 
and interquartile range. 
Comparison between treatment 
groups with Kruskal Wallis, 
Wilcoxon rank test and Mood 
Median test. For pairwise post-
hoc comparison, Dunn´s test was 
used.  
 
4.2 ETHICAL CONSIDERATIONS 
All the investigations in the studies conform to the principles outlined in the “Declaration of 
Helsinki”; from 1964.  Ethical approvals, from the Regional Research Ethics Boards were 
granted for all the four studies.  
Paper I and III (Regional Research Ethics Board Lund Dnr 42/2004 and 2009/524):   
For the EXPRESS study, the parents as the legal guardians of the infants, were informed 
about the purpose of the study (written and oral information) at the time of the admission of 
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the infant.  The method of passive consent was applied and if the parents did not consent to 
the data collection an active “withdrawal” was required. At the time of the follow-up study at 
6.5 years of age, the parents were again informed and a new written consent was acquired.   
The follow-up consisted of psychological testing, physiotherapy testing, ophthalmologist 
assessment, hearing assessment and pediatric evaluation. Furthermore, information on 
parental education was retrieved. No blood tests were included. The parents were informed of 
the results of all studies by the doctor, psychologist and physiotherapist.  
There are certain ethical concerns on neurodevelopmental follow-up in this category. For the 
parents to be reminded of their stay in the NICU and raising questions on the child´s 
neurodevelopment can be stressful.  The families with lower socioeconomic resources may 
not have as easy access due to inability or language issues. For children already diagnosed 
with disabilities it may be considered a discomfort for one more appointment. 
Paper II: (Regional Research Ethics Board Stockholm Dnr 2011/209-31/1 and 2011/1356-
32)  
As this was a European collaboration with 19 regions in 11 countries, ethical approval was 
obtained in each region in each country, as required by national legislation. Therefore, the 
parental consent procedure differed between regions, from active written consent to passive 
consent (information received and consent assumed if not stated otherwise). In the Stockholm 
region, parents were informed on the study after the admission of their infant.  Passive 
consent to the data collection was applied.  
Paper IV: (Regional Research Ethics Board Stockholm Dnr 2011/772-31/4 and 2011/1253-
32) 
Parents, as the legal guardians, were informed both orally and with written information about 
the study protocol before or after birth of their child. Parental written consent for inclusion 
was acquired after birth.  
Extremely preterm infants are a vulnerable population and their families are in a state of 
shock in relation to the birth of their infant. This became most obvious in the study for paper 
IV. Precautions were taken from the beginning in the study protocol to minimize both the 
infant´s discomfort and potential blood loss due to study samples. Echocardiography 
investigations were part of routine care of the infants. Blood samples were needed to measure 
levels of cardiac biomarkers. Initially, extra study blood samples were required as to fulfill 
blinding towards the clinician in charge of the infant.  For all study blood tests, the upper 
limit of maximal 2.5mL blood per kg per month of included infants, was followed (taking 
into account other clinical studies requiring blood samples for research purposes). During the 
first 4 months of the study, parental concerns over additional blood loss due to study blood 
sampling became a hindrance as the parents declined study participation. Therefore, the 
protocol was revised and the ethical permission amended to include the study tests from 
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blood samples already taken for clinical purposes, thereby minimizing patient discomfort and 
blood loss. 
4.3 STATISTICAL METHODS 
Descriptive methods were used when appropriate: means (with standard deviations, SD), 
medians (with interquartile ranges 25th to 75th percentile, IQR) and numbers (with 
proportions) were used.   
In paper IV, time to event curves (Kaplan-Meier estimator/curve) were used to describe the 
incidence of ductal closure over time, from birth to 40 weeks PMA. This allowed censoring 
at time of death, transfer to hospital out of county or surgical closure of the PDA, whichever 
occurred first. 
To test for normality of continuous data, Shapiro Wilk’s and Anderson Darling tests were 
used. T-test was used for comparison of normally distributed data. In cases where normal 
distribution of data was not confirmed, non-parametric tests were used for comparison, 
Wilcoxon rank-sum or Mood Median tests if only two groups were compared, and Kruskal 
Wallis test for group comparisons of more than two groups. For post hoc pairwise 
comparison, Dunn´s test was used. For comparison of proportions, χ2 test or Fischer´s exact 
test was used. To compare Kaplan-Maier curves, the χ2 method using Log-rank and 
Wilcoxon non-parametric tests were performed.  
To select covariates and confounders of interest for adjustment in the regression analysis, 
various methods were used in the papers (described separately in each paper). 
Regression models used (dependent on type of data; continuous, categorical, dichotomous or 
time-dependent).  
• COX proportional hazards model (time-dependent), presented as hazard ratio (HR) 
with 95% confidence intervals (CI). 
• Logistic regression (binomial distribution) presented as odds ratio (OR) with 95% 
confidence intervals (CI), 
• Linear regression models (Gaussian distribution) presented as risk ratios (RR) with 
[95% confidence intervals (CI)]. 
• Mixed-effects generalized linear regression models (with Poisson distribution) 
presented as risk ratio (RR) (paper II) and incidence rate ratio (IRR) (paper III) with 
[95% confidence intervals (CI)] 
Clustering was accounted for in the analyses in papers I, II and III. This is due to the risk of 
similarities between 1) infants born in the same region or cared for in the same neonatal unit 
2) siblings (multiple birth).  
A p-value of <0.05 was considered significant in the analysis.  
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Statistical software used:  All statistical analyses were performed using STATA SE13.1 and 
IC15 (http://www.stata.com/), Microsoft Excel version 1808 (https://products.office.com/en-
us/excel) and Minitab Statistical Software Version 17 (http://www.minitab.com). 
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5 RESULTS 
5.1 PAPER I 
The median postnatal age (PNA) at start of PDA treatment was 4 days, (IQR 2-7). PDA 
surgery after prior pharmacological treatment (secondary PDA surgery) was performed on 
102 infants (35%).  The three categories did not differ regarding obstetric background 
variables, birth weight, GA, sex, CRIB score (Clinical Risk Index for Babies) or early 
surfactant administration. Twenty-eight infants (10%) died between the start of treatment and 
before 36 + 0 weeks of PMA. Of these 25 infants died before 28 days of age.   
 
Figure 5.1.1 Overview of the 290 infants in the cohort and categorization according to 
timing of treatment. The outcomes, secondary PDA surgery, death <28 days or no 
further PDA treatament are detailed. 
The proportion of death differed between the three treatment categories as shown in Figure 
5.1.1 above, with the highest proportion among those who started PDA treatment early.   
Risk of PDA surgery 
As shown in Figure 5.1.2, there were no significant differences in risk of PDA surgery or 
death detected between the three groups (early treatment as reference group). In the crude 
analyses, a higher GA was associated with a lower risk of the composite outcome, secondary 
PDA surgery or death (HR 0.61 with 95% confidence interval, [CI 0.52–0.72] per week 
increase in GA).  In a model stratified on GA and adjusted for clustering on region, HR for 
late and intermediate vs early start was 1.10 [CI 0.53–2.28] and 0.89 [CI 0.57–1.39] 
respectively.  
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Figure 5.1.2. Risk of later PDA surgery after different timing of NSAID 
pharmacological treatment (categorized as early, intermediate and late start). The cox 
regressions model is stratified on GA and adjusted for clusterin on region.   
Abbreviations: HR:hazard ratio. CI: confidence interval.  
Association between timing of pharmacological treatment and risk of BPD 
Two hundred and fifty-nine infants (89%) survived to 36 weeks PMA and had available data 
on oxygen treatment. Of these, 166 (64%) were defined as having BPD. The duration of 
mechanical ventilation differed between the categories of timing of PDA treatment. The 
duration was significantly shorter among infants with early start of treatment. In the late start 
group, fewer infants were treated with mechanical ventilation. However, when all treatment 
groups were compared on postnatal day 7, no significant difference in the proportion of 
infants on mechanical ventilation was found. 
Risk for BPD according to early, intermediate or late start of pharmacological treatment is 
shown in Figure 5.1.3.  Late start of PDA treatment was associated with a significantly lower 
risk of BPD OR 0.29 [CI 0.13-0.61] compared to early start of treatment. 
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Figure 5.1.3.  Risk of BPD according to timing of NSAID pharmacological PDA 
treatment (categorized as early, intermediate and late start). Logistic regression model 
stratified on GA and adjusted for sex and SGA (adjusting for duration of ventilation 
did not changes the estimates).   
Abbreviations: OR: odds ratio. CI: confidence interval. GA: gestational age. SGA: small for gestational age.  
 
Key points Paper I: 
• Neither late start of pharmacological PDA treatment (at ≥7 days of age) 
nor intermediate (3-6 days of age) was associated with an increased risk 
for PDA surgery or death compared to an early start of treatment (0-2 
days of age).  
 
•  A high proportion of extremely preterm infants died in the first weeks of 
life and this had to be accounted for in the analysis by a combined 
outcome of PDA surgery or death.  
 
• Due to different age at start of pharmacological treatment as well as time 
at risk for surgery, the COX proportional hazard regression was chosen to 
account for the at-risk time (up to 90 days of age).   
 
• Gestational age is an important predictor of PDA treatment. 
 
• Later pharmacological PDA treatment seems to be a safe treatment 
option.  
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5.2 PAPER II 
In the cohort of the study in paper II, the mean GA in the cohort was 29.1 weeks (SD 2.2) and 
mean birthweight 1223 grams (SD 384). The total proportion of any PDA treatment was 
20%. Of infants born at less than 28 weeks, 44% were treated for PDA and 9.8% of infants 
born at 28 to 31 weeks. PDA treatment was strongly associated with GA, see figure 5.2.1. 
Figure 5.2.1. 
 
Figure 5.2.1 Proportion of PDA treatment according to gestational age in weeks in the 
EPICE cohort. © 2017 S. Karger AG, Basel. Published with permission. 
Differences in infant characteristics were studied using a propensity score derived from 
perinatal risk factors for PDA treatment. When variation between regions was studied, the 
proportion of PDA treatment varied significantly, from 10 to 39% between regions (p < 
0.001). The regions were categorized according to low (<15%, n = 6), medium (15–25%, n = 
9), or high (>25%, n = 4) proportion of PDA treatment. The difference in PDA treatment 
could not be explained by differences in perinatal characteristics as displayed by propensity 
score (see Figure 5.2.2). 
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Figure 5.2.2. In the 2 categories of gestational age born at <28 weeks and at 28-32 weeks 
the proportion of PDA treatment in the regions (categorized into low, medium or high) 
are shown in relation to propensity score. © 2017 S. Karger AG, Basel. Published with 
permission. 
Infants treated for PDA, compared to those not treated, were at higher risk of BPD or death in 
all regions, with an overall propensity score adjusted risk ratio of 1.33 (95% confidence 
interval 1.18–1.51), see Table 5.2.1.  Survival without major neonatal morbidity (IVH grade 
≥ 3, cystic periventricular leukomalacia (PVL), necrotizing enterocolitis requiring surgery or 
peritoneal drainage, or retinopathy of prematurity stage ≥ 3) was not related to PDA 
treatment.  
 40 
Table 5.2.1. Numbers and adjusted risk ratios (95% confidence intervals) for the composite outcomes of BPD or 
deatha, and survival without major neonatal morbidityb according to PDA treatment (Y/N) or type of PDA treatment 
in 19 European regions with low (<15%), medium (15-25%) or high proportions (>25%) of PDA treatment.  
 
Low 
N=2,875 
Medium 
N=3,417 
High 
N=604 
No. of 
events  
aRR 
 (95% CI)c 
No. of 
events 
aRR  
(95% CI)c 
No. of 
events 
aRR  
(95% CI) c 
COMPOSITE OUTCOME OF BPD OR DEATH1 
No PDA treatment 523 1.00 (ref) 327 1.00 (ref) 45 1.00 (ref) 
Any PDA treatment 228 
1.26               
(1.06-1.49) 
294 
1.34                   
(1.12-1.61) 
96 
2.20              
(1.47-3.28) 
By type of PDA treatment 
Pharmacological treatment only 166 
1.21             
(0.98-1.50) 
205 
1.27                   
(1.05-1.55) 
68 
2.11             
(1.40-3.17) 
Surgery after pharmacological treatment 36 
1.36  
(0.94-1.98) 
72 
1.51                   
(1.22-1.86) 
17 
2.66              
(1.41-5.02) 
Surgery without prior pharmacological 
treatment 
26 
1.45             
(1.20-1.75) 
17 
1.79                    
(1.27-2.53) 
11 
2.76              
(1.45-5.24) 
SURVIVAL WITHOUT MAJOR NEONATAL MORBIDITY2 
No PDA treatment 2091 1.00 (ref) 2321 1.00 (ref) 349 1.00 (ref) 
Any PDA treatment 223 
1.03 
 (0.94-1.13) 
522 
1.03  
(0.96-1.10) 
165 
0.98  
(0.88-1.09) 
aAny oxygen treatment at 36 weeks of postmenstrual age (PMA) or death before 36 weeks PMA. 
b Survival to hospital discharge without intra-ventricular hemorrhage (IVH) grade≥3, cystic periventricular leukomalacia 
(cPVL), retinopathy of prematurity (ROP) stage ≥3, surgical NEC. Total N=6,335 survivors. 
c Results from a generalized linear mixed model adjusted for propensity score for PDA treatment.  The propensity score for 
PDA treatment, i.e., a single index variable summarizing the pre-treatment perinatal characteristics, was estimated from 
presence of preeclampsia/eclampsia, spontaneous onset of labor, preterm premature rupture of membranes (pPROM), 
maternal infection as indication for delivery, antenatal corticosteroid treatment, mode of delivery, gestational age, birth 
weight, infant sex, small for gestational age and use of mechanical ventilation on first day of life. 
Abbreviations: aRR: Adjusted Risk Ratio 
© 2017 S. Karger AG, Basel. Published with permission. 
 
 
Key points Paper II: 
• In infants born at <32 weeks of age, PDA treatment varied largely across Europe 
without associated variations in perinatal characteristics. 
 
• PDA treatment was strongly associated with GA. 
 
• Infants treated for PDA, compared to those not treated, were at higher risk of 
BPD or death in all regions. 
  
• Survival without major neonatal morbidity was not related to PDA treatment. 
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5.3 PAPER III 
The characteristics of the infants in paper III are described in the manuscript. Children treated 
with PDA surgery had lower GA and birthweight and higher CRIB II score. They had longer 
duration of mechanical ventilation and were more often treated with postnatal steroids than 
children not treated for PDA. Children who had primary PDA surgery were more often 
diagnosed with IVH grade 3 or higher and had the highest proportion of BPD. IVH grade 1-2 
was evenly distributed between the categories.  
Neurodevelopmental outcome by PDA category 
The proportion of extremely preterm born children with moderate to severe NDI varied from 
27% in the group not treated for PDA to 55% in children who had primary PDA surgery, see 
Figure 5.3.1a. 
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Figure 5.3.1a Distribution of NDI according to PDA treatment in 435 children, at 6.5 years of age, born at <27 weeks GA.  
Abbreviations: PDA: Patent Ductus Arteriosus. NSAID: Non-Steroidal Anti-Inflammatory Drugs. NDI: Neurodevelopmental Impairment. Tx: Treatment. GA: Gestational Age.  
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Figure 5.3.1b Distributions of FSIQ according to PDA treatment in 366 children, at 6.5 years of age, born at <27 weeks GA. Categorization 
according to results of term-born Swedish children tested with WISC-IV. FSIQ into SDs:  <-3SD (FSIQ<66); From-3SD to below -2SD (FSIQ 66-76); from-2SD to 
below -1SD (FSIQ 77-88); ≥-1SD (FSIQ >88). Abbreviations:  PDA: Patent Ductus Arteriosus.  NSAID: Non-Steroidal Anti-Inflammatory Drugs. FSIQ: Full-Scale Intelligent Quotient. 
Tx: treatment. EXPRESS: Extremely Preterm Infants in Sweden Study. WISC-IV: Wecshler Intelligent Scales. SD: Standard Deviation. 
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In Figure 5.3.1b, the categories of FSIQ SD’s, are shown for all categories of PDA 
treatment. Children undergoing primary PDA surgery had the highest proportion of FSIQ 
below -3 SD (34%). 
The risk of moderate to severe NDI was 62% higher among children treated with primary 
PDA surgery in the adjusted model (see Table 5.3.1) than in extremely preterm born children 
not receiving PDA treatment. No increased risks of NDI were found among children treated 
pharmacologically for PDA, regardless of whether they later had surgical PDA closure or not.  
In analyses of 366 children that had FSIQ measured, extremely preterm born children treated 
with primary PDA surgery had significantly lower total FSIQ in the adjusted model, 
compared to extremely preterm born children not treated for PDA. Pharmacological PDA 
treatment, with or without later PDA surgery, was not associated with lower FSIQ in 
extremely preterm born children (See Table 5.3.1, shown as adjusted mean difference in 
FSIQ). 
Table 5.3.1 Association of PDA treatment category and NDI or FSIQ 
 N=435 Risk of NDI               
Adjusted IRR*             
[95% Cl]                  
N=435 
Adjusted mean            
difference in FSIQ*       
[95% Cl]                 
N=366                     
No PDA treatment 170 1.00 (ref) Ref. 
NSAID PDA treatment 139 1.23 [0.80-1.89] -1.2 [-4.8 to 2.4] 
PDA surgery after 
prior NSAID treatment 
88 1.09 [0.70-1.70] 1.2 [-2.5 to 4.8] 
Primary surgery 38 1.62 [1.28-2.06] -7.1 [-11 to -3.2] 
* adjusted for gestational age, sex, birth weight, SDS-score, maternal education, and intra-
ventricular hemorrhage grades 3 or higher  
Both postnatal steroids and BPD has been associated with risk of adverse 
neurodevelopmental but in the context of PDA they could be considered as mediators, when 
the association of PDA treatment to neurodevelopmental outcome is examined (they occur 
after PDA treatment which is the exposure). These adjustments were therefore made in a 
separate model for both NDI and FSIQ.  The NDI risk estimates were slightly attenuated, but 
still highly significant for primary PDA surgery. The estimates for the association between 
the other PDA treatment categories and NDI remained unchanged. Furthermore, adjustment 
for postnatal steroids and BPD did slightly attenuate the association between primary PDA 
surgery and FSIQ, however, it also remained highly significant  
Timing of PDA treatment 
The median age for primary PDA surgery in the cohort was 17 days (IQR 12-26), and 20 
days (IQR 13-26) for PDA surgery after prior NSAID treatment; p= 0.85. The risk of 
moderate to severe NDI was more than threefold, and the adjusted mean difference in FSIQ 
was -15 [95% CI: -19 to -12] among children operated at ≤10 days of age compared to 
children operated at ≥20 days of age. When all the children having PDA surgery were studied 
with timing of PDA surgery as exposure, the risk of moderate to severe NDI remained more 
than doubled in both early (at ≤10 days of age) PDA primary surgery and early PDA surgery 
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after prior NSAID treatment, while the FSIQ was no longer significantly associated with 
timing of surgery (see Table 5.3.2). The association of timing of surgical PDA treatment with 
moderate to severe NDI and FSIQ is shown in Table 5.3.2. 
Table 5.3.2. Moderate to severe Neurodevelopmental Impairment (NDI) and cognitive outcome (measured 
as FSIQa) by type and timing of PDA surgery at 6.5 years of age, after birth at <27 gestational weeks. 
 ≤10 days 11 -20 days >20 days 
PDA surgery, all (N=124)b   n= 23 n= 44 n= 57 
Number of children with moderate or severe NDI, n n=17 n=21 n=15  
Moderate to severe NDI, IRRc (95% CI) 3.26 [2.40 to 4.42]c 1.85 [0.99 to 3.44]c 1.00 (ref) 
Adjusted mean difference in FSIQd, (95% CI) -15 [-19 to -12]d -1.4 [-6.2 to 3.3]d 1.00 
PDA surgery, primary (N=37) n=7 n=15 n=15 
Number of children with moderate or severe NDI, n n=7 n=9 n=5 
Moderate to severe NDI, IRRc (95% CI) 2.35 [1.11 to 4.96]c 1.58 [0.77 to 3.24]c 1.00 
Adjusted mean difference in FSIQd, (95% CI) -14 [-30 to 1.6]d -0.65 [-15 to 14]d 1.00 
PDA surgery, after NSAID treatment (N=87) n=16 n=29 n=42 
Number of children with moderate or severe NDI, n n=10  n=12  n=10  
Moderate to severe NDI, IRRc (95% CI) 2.90 [1.62 to 5.22]c 2.07 [0.61 to 7.10]c 1.00 
Adjusted mean difference in FSIQd, (95% CI) -10 [-17 to -3.1]d -2.0 [-8.5 to 4.6]d 1.00 
aFSIQ: Full-Scale Intelligent Quotient measured by the Wechsler Intelligence Scale for Children, fourth edition 
(WISC-IV) 
bOf the 126 children having PDA surgery, only 124 had a date of surgery and were included in the analysis.  
cMixed effects Poisson model adjusted for GA, SDS birth weight, sex and IVH 3 or higher and maternal education 
with region and mother as random effect variable. 
dMixed effects linear model adjusted for: GA, SDS birth weight, sex and IVH 3 or higher and maternal education, 
with region as random effect variable. 
Abbreviations: NDI: Neurodevelopmental Impairment; FSIQ: Full-Scale Intelligent Quotient, WISC: Wechsler 
Intelligence Scale for Children, IRR: Incidence Rate Ratio; CI: Confidence Interval; SD: Standard Deviation. 
NSAID: Non-Steroidal Anti-Inflammatory Drugs, GA: Gestational Age, SDS: Standard Deviation Score. IVH: 
Intraventricular Hemorrhage 
 
 
 
Key points Paper III: 
• No association was detected between pharmacological PDA treatment or PDA 
surgery following prior pharmacological treatment in the neonatal period, and 
neurodevelopmental outcome at 6.5 years of age. 
 
• An increased risk of moderate to severe NDI and lower FSIQ was detected in 
children having primary PDA surgery.  
 
• When timing of PDA surgery was examined as an exposure, children who were 
operated at ≤10 days of age, compared to children operated >20 days of age, had 
the highest risk for moderate to severe NDI and lowest FSIQ.  
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5.4 PAPER IV 
Characteristics  
There were no differences in GA, birthweight and proportion of PDA treatment between the 
included and non-included infants. The mortality rate was similar, but infants not included 
died at an earlier age than infants included. In total, 12 included infants later died, at a median 
age of 14 days (IQR 14-16) and no deaths occurred in the group of infants having PDA 
operation. Median age at start of any PDA treatment was 8 days (IQR 5-11). Of the 24 infants 
born at <25 weeks of gestation, 20 (83%), received PDA treatment, the remaining four were 
not treated and died before PDA closure. Of the infants having PDA surgery, 9/22 (41%) 
were born at <25 weeks.  
PDA closure  
Eighty-two (84%) infants had a PDA closure date registered, which was 
echocardiographically confirmed or due to PDA surgery in 79 (81%) of the infants. Three 
infants were assigned a closure date at full term (40 weeks).  The remaining infants either 
died or were transferred before confirmed PDA closure. All infants with spontaneous closure 
of the PDA were born at ≥25 weeks of gestation. In Figure 5.4.1a, the probability for PDA 
closure for every day of life up to 40 weeks of PMA in infants born at <25 and at ≥25 weeks 
GA.  (Kaplan Meier curve with censoring on death, transfer out of county or on day of PDA 
surgery) at ≥25, see Figure 5.4.1a. Four infants born at less than 25 weeks did not have PDA 
surgery, i.e. closed their PDA after pharmacological treatment only. In Figure 5.4.1b the 
cumulative probabilities of PDA closure in infants treated for PDA or not are shown, after 
exclusion of infants who later died, were transferred or had PDA surgery (a total of 38 
infants). There was a significant difference in the 50% cumulative probability of PDA closure 
for treated vs not treated; by day 28 for infants spontaneously closing their duct and by day 
51 for ibuprofen treated (p-value= 0.03).
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Figure 5.4.1a. Probability of PDA closure by gestational age. Censoring protocol is 
shown in paper IV. 
 
Figure 5.4.1b Probability of PDA closure in infants not treated vs only ibuprofen 
treated. Censoring protocol is shown in paper IV. 
Echocardiographic markers of ductal severity  
In table 5.4.1 the echocardiographic characteristics on day 3 and day 7 are shown.  
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Table 5.4.1. Echocardiographic markers at different times in different PDA treatment categories. 
98 infants in the cohort No PDA 
treatment 
Ibuprofen only PDA 
treatment 
Surgical PDA 
treatment 
  
N=40 N=36 N=22   
On day 3 (range 2-4)a       P-valueg 
Bidirectional shunt, or right to left 
through duct, n (%) 
N=26 N=21 N=16 
 
8 (30.8) 1 (4.8) 3 (18.8) 0.078 
Ductal diameter, mm, median (IQR)  N=22 N=23 N=15 
 
1.3 (1.2-1.7) 1.9 (1.7-2.0) 1.7 (1.6-1.9) 0.002 
Vmax through duct, m/s, median 
(IQR)b 
N=16  N=20 N=12 
 
1.6 (1.2-2.4) 1.3 (1.1-1.9) 1.3 (1.2-1.6) 0.327 
Vmax-Vmin through the duct, m/s, 
median (IQR)b 
N=16 N=20 N=12 
 
0.9 (0.6-1.2) 0.9 (0.7-1.0) 0.9 (0.7-1.0) 0.675 
Resistance index, n (%), median 
(IQR)b 
N=15 N=20 N=12  
 
0.7 (0.6-2.8) 1.1 (0.7-1.6) 1.2 (0.8-2.2) 0.213 
La:Ao ratio, median (IQR) N=27 N=18 N=16 
 
1.4 (1.2-1.6) 1.6 (1.4-1.9) 1.7 (1.6-1.8) <0.001 
Pulmonary (LPA or RPA) end-
diastolic flow >0,2m/s, n (%) 
N=26 N=18  N=16 
 
4 (15.4) 4 (22.2) 11 (68.8) 0.001 
Signs of ductal stealc, n (%) N=31 N=21  N=16 
 
2 (6.5) 8 (38.1) 7 (43.8) 0.005 
On day 7 (range 5-9)e, f       P-valueg 
Bidirectional, or right to left flow 
through duct, n (%) 
N=29 N=33 N=20 
 
6 (20.7) 4 (12.1) 2 (10.0) 0.506 
Ductal diameter, mm, median (IQR) N=25 N=31  N=17 
 
1.6 (1.4-1.9) 1.6 (1.4-2-0) 1.8 (1.5-2.0) 0.411 
Vmax through duct, m/s, median 
(IQR)b 
N=19 N=29 N=17 
 
1.8 (1.5-2.7) 1.7 (1.5-2.2) 1.3 (0.9-1.6) <0.001 
Vmax-Vmin through the duct, m/s, 
median (IQR)b 
N=19 N=29 N=17 
 
1.2 (1.0-1.4) 1.1 (0.9-1.3) 0.8 (0.6-1.0) 0.016 
Resistance indexc, n (%), median 
(IQR) 
N=19 N=29 N=17 
 
0.8 (0.7-8.0) 2.0 (0.8-2.3) 0.9 (0.7-3.0) 0.481 
La:Ao ratio, median (IQR) N=31 N=29 N=16 
 
1.5 (1.3-1.5) 1.5(1.4-1.8) 1.6 (1.4-1.7) 0.037 
Pulmonary (LPA or RPA) end-
diastolic flow >0,2m/s, n (%) 
N=27 N=28  N=15 
 
8 (29.6) 11 (39.3) 0 (0) 0.021 
Signs of ductal steald, n (%) N=32 N=30 N=19 
 
7 (21.9) 15 (50.0) 6 (31.6) 0.064 
a5 infants had closed their duct on the day 3 echocardiography. bWhen bidirectional shunt through duct, Vmax and Vmax-
Vmin were not registered. cResistance index calculated as: (Vmax-Vmin)/Vmax. Vmax and Vmin measured through the 
duct. dDuctal steal was defined as any of: reversed diastolic flow in descending aorta, absent or reversed diastolic flow in 
mesenteric arteries, absent or reversed diastolic flow in anterior cerebral artery. e4 infants had closed ducts on day 7 
echocardiography, i.e. a total of 9. fSome had already started ibuprofen treatment. gDifferences between treatment 
categories tested with Kruskal Wallis test.  
Abbreviations:  PDA: patent ductus arteriosus. IQR: interquartile range. Vmax: maximal velocity. Vmin: minimal 
Velocity.. La:Ao: Left atrial to Aortic root. LPA: left pulmonary artery. RPA: right pulmonary artery. 
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Figure 5.4.2. The echocardiographic markers ductal diameter and maximal velocity 
through duct (Vmax) on day 3 in the three PDA categories.  
 
 
Figure 5.4.3. The echocardiographic markers ductal diameter and maximal velocity 
through duct (Vmax) on day 7 in the three PDA categories.  
Biomarkers 
cTnT values were not associated with spontaneous PDA closure or treatment for PDA. 
Among 6 infants closing their duct spontaneously at ≤7 days, NT-proBNP was significantly 
lower on day 3, median 1810 ng/L (IQR, 1760-6000) compared to infants closing 
spontaneously at >7 days, 10900 ng/L (6120-19200); treated for PDA either with ibuprofen 
only, 14600 ng/L (7740-28100); or undergoing PDA surgery, 32300 ng/L (29100-35000). 
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Infants who later received PDA surgery had significantly higher NT-proBNP values than all 
the other groups on day 3. This is illustrated in Figure 5.4.4.   
 
Figure 5.4.4 NT-proBNP in relation to PDA characteristics in infants born at <28 weeks 
of gestation. 
Overall comparison between the groups on both day 3 and day 7 showed significant 
differences (p=0.001 and p=0.003 respectively) On day 3: In pairwise comparisons (Dunn’s 
test): p<0.05 between spontaneous PDA closure ≤ 7 days and all other PDA categories, and 
between all other PDA categories and any PDA surgery. There was no significant difference 
between no PDA treatment (with open duct beyond first week of life) and ibuprofen 
treatment only.  On day 7: p<0.05 for all pairwise comparisons, except for the difference 
between ibuprofen only and any PDA surgery. 
  51 
 
 
Key points Paper IV: 
• 59 % of the infants received any PDA treatment at a median age of 8 days 
(IQR 5-11) and 26% of infants received ibuprofen at an age of >7 days. 
 
•  One third of infants, of whom all were born at ≥25 weeks, closed their duct 
spontaneously, with a 50% probability of closure by day 28.  
 
• Infants closing their duct spontaneously at ≤7 days had significantly lower 
NT-proBNP levels on day 3 and 7 compared to all other PDA categories. 
 
• Infants who later had PDA surgery had significantly higher NT-proBNP 
levels on day 3 and 7 compared to all the other PDA categories. 
 
• cTnT values were not associated with spontaneous PDA closure or treatment 
for PDA. 
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6 DISCUSSION 
6.1.1 Importance of studies 
The studies described in this thesis are cohort studies of extremely and very preterm infants 
conducted over a ten-year period. Two of the three cohorts are large population-based cohorts 
and include 2501 infants born at less than 28 weeks of gestation. Thereby, the studies are 
representative for the population in today´s neonatal units as the most complex PDA 
problems arise in infants born at less than 28 weeks of gestation. With the variation in 
treatment strategies the last decade, well designed observational cohort studies are 
informative, even though the PDA treatment strategies investigated are changing.5,10 The 
design of the studies and the extensive prospective data collection make it possible to 
investigate the association between PDA and short and long-term outcomes after extremely 
preterm birth. The European EPICE cohort is very large and represents European PDA 
treatment well.14Although the infants in the EXPRESS cohort were born 15 years ago, the 
results from the cohort are still relevant, as the mean GA is 25.3 weeks and they received 
antenatal steroids to a high degree (90%), which is associated with optimal care and the best 
chances of survival.13,112 Furthermore, the extensive neurodevelopmental assessment at 
school-age in paper III is informative, as it is important to evaluate neurodevelopment at an 
age that is sufficiently advanced to be predictive, yet young enough to benefit from 
modifying interventions (such as behavioral interventions and intensive physiotherapy). The 
EXPRESS and the EPICE cohorts do not have information on the echocardiographic 
diagnostics of the PDA, but the DEDUCT cohort in paper IV has that information, which 
makes it an informative study on diagnostics of the PDA, with combination of 
echocardiography and biomarkers.  
6.1.2 Variation in PDA treatment 
In the population-based EPICE cohort of very preterm infants, there were large differences in 
PDA treatment without associated variations in perinatal characteristics. Local treatment 
guidelines, if existing, varied (personal communication Anna-Karin Edstedt Bonamy). At the 
time of the EPICE study, the evidence for PDA treatment and association with outcomes was 
debated just as it is today. Different treatment strategies were practiced and in certain centers 
PDA treatment was abandoned.113-115 Rates of both pharmacological and surgical PDA 
treatment have been declining worldwide. In the USA, rates of PDA treatament were 
compared from 2006 to 2015 with significant decreasing rates of PDA diagnosis, 
pharmacological treatment and PDA surgery.5 In Sweden, the PDA treatment rates have also 
declined, from a rate of 60% during the EXPRESS study period 2004-2007 to approximately 
40 % during 2016-2017.4,21 The associations of these changes, if any, to incidence of neonatal 
morbidity is not fully examined or understood. 
All studies described in papers I-IV are limited due to heterogenous data. In paper I-III the 
PDA treatment decision is based on PDA diagnosis which has low precision due to lack of 
data on echocardiographic details of the ductal severity and certain clinical variables. In paper 
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I, this may introduce a bias in the group treated at ≥7 days, as they may solely have been 
treated in the window of opportunity for ibuprofen, and not due to the ductal severity. In 
paper II, this introduces uncertainty in the interpretation of the variation in PDA treatment 
and especially in understanding of the association between PDA treatment and BPD. 
Evaluation of the PDA severity and the duration of the ductal shunt with echocardiography 
are very important factors in understanding the association between PDA and outcomes after 
treatment in extremely preterm infants.73 In paper III, the untreated infants are likely a mix of 
infants not treated who closed their ducts, and infants who had a significant ductal shunt, but 
were never actively treated (conservative treatment was not registered). In paper IV, the 
echocardiographic severity is known, but due to methodological complications, data is 
heterogenous because of different timepoints of echocardiographies and biomarker values.  
Furthermore, there were >10 neonatologists who performed echocardiography of the included 
infants, which may have introduced an inter-operator variability.   
Biomarkers as a complement to scoring systems of echocardiographic and clinical PDA 
severity is an attractive approach, as they are not dependent on echocardiographic resources 
or associated with inter-operator variability.67 In our study, we found that NT-proBNP on day 
3 is predictive of later PDA surgery in infants born at <28 weeks. Furthermore, infants with 
very low levels of NT-proBNP on day 3 closed their ducts spontaneously at ≤7 days of age. 
Infants, who later were treated with either ibuprofen only or later surgery had on day 3 an 
echocardiographically hsPDA (as defined by local guidelines as well as international scoring 
systems).35This indicates that the PDA treatment decision in the cohort is in line with the 
echocardiographic severity of the duct but the associations of NT-proBNP and the 
echocardiographic markers need to be further studied. In the group of infants not treated, the 
echocardiographic markers on day 3 were more varied, which can be explained by the fact 
that the group included both infants closing the duct spontaneously and infants who later 
died. In studies using the same NT-proBNP laboratoy analysis method, an association 
between NT-proBNP levels and PDA treatment were seen in cohorts of more mature 
infants.79,80 This could support the role of NT-proBNP as a proxy for ductal severity.  
6.1.3 Covariates  
 All three cohorts in the papers had information on many covariates and confounders, mostly 
perinatal and early neonatal. In general, the cohort characteristics did not differ substantially. 
The one characteristic of most importance for PDA treatment was GA, which confirms what 
other studies have shown.29 Other covariates of importance for the specific outcomes were 
expected, such as SGA and mechanical ventilation for BPD and IVH and maternal education 
for neurodevelopmental outcome.110,116,117 We have taken clearly defined perinatal and early 
neonatal factors into account, but the more detailed temporal relation of morbidities, which 
mostly are between the exposure and the outcome and therefore determined as mediators, are 
not as well defined in our cohorts. An example of such is sepsis which is related to long-term 
outcomes, such as neurodevelopmental outcome.118However, in these studies factors such as 
nutrition in context with PDA treatment has not been examined. It has been confirmed in the 
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EXPRESS cohort that infants undergoing PDA surgery had suboptimal nutrition.119 This is a 
factor that needs consideration. Furthermore, retinopathy of prematurity (ROP) was not 
studied, but is an interesting morbiditet both as a mediator for later neurodevelopmental 
outcome and as an outcome after PDA treatment. 
6.1.4 Gestational age  
In paper I, the contribution of every week increase in GA was substantial in decreasing the 
risk of PDA surgery or death. In paper II, the risk for PDA treatment was also strongly 
associated with GA. Studies on spontaneous closure of PDA support this, but due to high 
treatment rates these studies are scarce.29-32 In paper IV, all infants spontaneously closing 
their duct were born at ≥25 weeks. 
Gestational age is strongly associated with both the need of PDA treatment and 
neurodevelopmental outcome, as is confirmed in our study in paper III, and therefore the 
most important confounder.15,120  The exact contributions of IVH, GA, and PDA to 
neurodevelopmental outcome remain to be explored, as GA is a strong predictor of both IVH 
and PDA. 
6.1.5 PDA closure   
PDA closure has been the goal of PDA treatment and has been the outcome used for 
evaluating the efficacy of pharmacological treatment and later need for PDA surgery.  
Nevertheless, studies that can confirm the time of PDA closure are lacking in the literature 
(except when closed with PDA surgery). In paper IV, we could study PDA closure as 
longitudinal echocardiographies were performed. Spontaneous closure rate was similar and 
even higher in paper IV than earlier reported in extremely preterm infants.29 Studies have 
confirmed that even infants born in the lowest GA’s can close the duct spontaneously, but 
information on conservative treatment such as diuretics are lacking.30,32 Spontaneous ductal 
closure rate in infants born <25 weeks is still difficult to study due to high PDA treatment 
rates.121In paper II, it is noted that infants born in weeks 28-32 of gestation are still being 
treated for PDA to a high extent in some regions. Current evidence argues that in most cases 
this is unnecessary.29,31  
6.1.6 Timing of PDA treatment  
Early studies on PDA treatment with NSAIDs showed that prophylactic or early treatment 
was associated with higher PDA closure and lower rates of PDA surgery.122,123 These studies 
did not account for probability of spontaneous PDA closure.29 Trials on early treatment 
compared with expectant management (day 3 vs day 7 to 11) did not show differences in 
frequency of later PDA surgery.105,124 Furthermore, efficacy of NSAIDs on PDA closure is 
highest within the first 2-3 weeks of life.125 It can be deducted that this has been a driving 
factor in the PDA treatment strategies studied and practiced through the years. In our studies, 
we had the opportunity to examine the timing of treatment, both pharmacological and 
surgical as an exposure. In paper I, in the Swedish EXPRESS cohort, infants treated at > 7 
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days of age compared to 0-2 days or 3-6 days did not have higher risk of PDA surgery or 
death, or later BPD. In a newly published study where start of treatment at more than 6 days 
of life was investigated, later PDA treatment were not associated with higher rates of PDA 
surgery or presence of PDA at discharge compared to earlier start of treatment.126  
Furthermore, there was no difference in the incidence of BPD between the two groups. In 
paper III, school-aged children undergoing PDA surgery at ≤10 days of age, compared to at 
>20 days of age, had the highest risk for moderate to severe NDI and lowest FSIQ. In the 
models, adjustments were made for many of the important confounders such as maternal 
education. Wickremashinge et al have earlier discussed that timing of PDA surgery is of 
importance when studying later neurodevelopmental outcome and physiologically the 
immature infant has less resilience to the hemodynamic challenge of PDA surgery early in 
life.94  
6.1.7 PDA and BPD  
BPD is studied as an outcome in papers I, II and as a mediator in paper III.  The association 
between PDA and BPD is complex with many common risk factors. In theory, a shorter 
duration of the PDA shunt and thus shorter period of excessive pulmonary circulation could 
be beneficial. Results of trials and cohort studies have been contradictory; PDA treatment has 
been associated with both decreased and increased pulmonary morbidity and development of 
BPD.103,127 In paper I, early pharmacological PDA treatment was not associated with lower 
risk of BPD compared to late start of PDA treatment. Other cohort studies have supported 
these findings.128 In a few contemporary randomized trials, one of them using prophylaxis 
with indomethacin (TIPP trial) and two on early vs expectant management, there was no 
difference in BPD incidence or mortality between infants receiving early NSAIDs and later 
treatment or placebo.93,105,126 In the EPICE study, paper II, any PDA treatment was associated 
with the risk of BPD. Furthermore, infants born in regions with high proportion of PDA 
treatment had higher BPD risk compared to low proportion of PDA treatment. This can be 
due to a more pro-active surgery approach in the high proportion regions, or to suboptimal 
care. PDA surgery has been associated with higher risk of BPD, though it is debated that it is 
due to confounding of indication.127 Studies on prophylactic PDA surgery described an 
increase in BPD, despite shorter mechanical ventilation.9,103,129 A limitation of our studies in 
paper I and II, is the lack of knowledge on exact ductal shunt time, as the exact date of ductal 
closure is not known (unless when date of surgery). This information would be helpful for 
understanding the association of PDA and BPD and can be explored in the cohort in paper IV 
as the data is collected for further analyses.  
6.1.8 PDA and neurodevelopmental outcome 
Active PDA closure in extremely preterm infants has not been convincingly shown to 
improve long-term neurodevelopmental outcome.11 In fact, PDA treatment has been 
associated with adverse neurodevelopmental outcome at two to three years of age compared 
to untreated children.24,25,27 It is debated what the benefits of PDA surgery are and if they 
outweigh the risk with surgery in such a vulnerable population as extremely preterm infants.  
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It has been suggested that the associations between PDA treatment and adverse 
neurodevelopmental outcome may result from confounding by indication or survival bias as 
well as early timing of surgery.98,130 In paper III, an association could not be detected between 
pharmacological PDA treatment or PDA surgery following prior pharmacological treatment 
in the neonatal period and later neurodevelopmental outcome. Children having primary PDA 
surgery, on the other hand, had increased risk of moderate to severe NDI and lower FSIQ 
compared to children not treated. This was supported by a recent cohort study, in which PDA 
surgery was not associated with NDI at 18-24 months of age when adjusted for both perinatal 
and preligation neonatal risk factors.106 In that study, all PDA surgery was investigated as one 
exposure, regardless of whether primary or not.106 In our study in paper III it was possible 
both to explore PDA surgery with and without prior ibuprofen treatment and to explore the 
association between timing of PDA surgery and later outcome. In all children undergoing 
PDA surgery  at ≤10 days of age, compared to surgery at >20 days of age, the highest risk for 
moderate to severe NDI and lowest FSIQ was in the group operated early (<10 days). The 
increased risk for adverse neurodevelopmental outcome observed after primary PDA surgery 
in our study was explored. Earlier timing of the PDA operation was one of them and 
incidence of IVH grade 3 or higher, in the group having primary PDA surgery was another 
but even after adjustment were made for these and other several potential confounders the 
association remained significant. Confounding, either residual or by indication, is still 
possible though, as the temporal relationship of comorbidities was not known and lack of 
power for IVH cannot be excluded. It has been discussed that BPD is a risk factor for adverse 
neurodevelopment. This was confirmed in a recent a meta-analysis of cohort studies.131 In the 
analyses in paper III, this was approached as we adjusted for the potential mediators, 
postnatal steroids (given to treat pulmonary morbidity) and BPD, but that did not change the 
association between PDA treatment and risk for adverse neurodevelopmental outcome. 
Future studies should elucidate the role of PDA and its treatment in the evolvement of BPD, 
and further examine their role on neurodevelopmental outcome.
 58 
6.2 EPIDEMIOLOGICAL CONSIDERATIONS 
Table 6.2.1 Overview of epidemiologic and statistical considerations in all the studies in the thesis 
 Study I Study II Study III Study IV 
Design Prospective cohort 
study 
Prospective cohort 
study 
Prospective cohort 
study 
Prospective cohort 
study 
Population, 
period and 
gestational age 
EXPRESS  
Sweden 
2004-2007 
<27 weeks 
EPICE  
Europe  
2011-2012 
<32 weeks 
EXPRESS  
Sweden  
Born 2004-2007 <27 
weeks 
Follow-up 2010-2013 
DEDUCT  
Stockholm 
2012-2014 
<27 weeks 
Number of infants 
included 
290 6896 435 98 
Power consider-
ations 
In a sample of 290 
infants having NSAID 
PDA treatment, the 
power was 80% to 
detect a HR of 1.45, as 
127 infants had later 
PDA surgery or died. 
(alfa-level of 0.05).  
 
 
Large population-based 
cohort so assumed that 
power is not an issue. 
In a sample of 435 
children, with 4 
treatment categories, 
the power was 80% to 
detect differences in 
FSIQ of 4 in overall 
analysis and of 11 in 
analysis for timing of 
surgery. (mean FSIQ 
100 and SD 15 in the 
comparison group) 
(alfa-level 0.05) 
In a sample of 80 
infants where 50% 
have a hsPDA, the 
power is 80% to detect 
a difference in 
biomarkers with SD 
<0.5, between infants 
with hsPDA and 
minimal or closed DA 
(alfa-level of 0.05) 
Age at inclusion Alive at 24 hours of 
age 
Alive at 24 hours of 
age 
Alive at 6.5 years of 
age at follow-up. 
Alive at inclusion (up 
to 72 hours of age)  
Definition and 
diagnostics of the 
exposure 
Echocardiographically 
verified PDA, treated 
with NSAIDs. 
Echocardiographic data 
not available (i.e. 
ductal severity not 
known) 
PDA treated with 
NSAIDs and PDA 
surgery. 
Echocardiographic data 
not available (ductal 
severity not known) 
Echocardiographically 
verified PDA treated 
with NSAID´s and/or 
PDA surgery. 
Echocardiographic data 
not available (ductal 
severity not known) 
Echocardiographically 
verified hsPDA.  
Ductal severity known. 
Heterogenous 
population in 
exposure 
categories  
Ductal severity not known due to non-availability of echocardiographic data 
and therefore uncertainty about the indication for treatment 
Due to delayed or 
deferred blood 
sampling or 
echocardiography, the 
biomarkers and 
echocardiography 
markers results can be 
heterogenous 
Outcomes  Composite outcomes:  
1) PDA surgery or 
death 
2) BPD at 36 weeks 
PMA in survivors 
Composite outcome  
1) BPD or death  
2) Survival without 
major neonatal 
morbidity 
NDI and FSIQ at 6.5 
years of age in 
survivors 
PDA closure 
-spontaneous 
-ibuprofen treatment 
only 
-PDA surgery 
 
Examples of bias Survival bias 
Selection bias 
Survival bias 
Selection bias 
Selection bias Survival bias 
Selection bias 
Clustering Addressed Addressed Addressed Not addressed 
Other analytical 
considerations 
At risk time-period 
handled with the COX 
proportional hazards 
regression model (from 
treatment start and up 
to 90 days of age). 
Temporal relationship 
of morbidities, such as 
sepsis would have been 
optimal to account for.  
Perinatal factors in the 
propensity score and 
adjusted for one factor 
instead of many 
covariates. Temporal 
relationship 
morbidities, such as 
sepsis, would have 
been optimal to 
account for. 
Power concerns in 
primary PDA surgery 
group. 
BPD and postnatal 
steroids in the mediator 
pathway and therefore 
“not correct” to adjust 
for.  Mediator analysis 
tested, but no 
difference in results 
compared to usual 
regression analysis. 
What is the most 
optimal outcome in this 
study?  
Echocardiographically 
verified PDA closure 
was chosen.  Treatment 
of PDA was at the 
discretion of the 
neonatologist in 
charge. What is the 
gold standard?   
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6.2.1 Bias   
The role of bias in studies on PDA is debated and many have pointed out the importance of 
taking the risk of bias to account in the study design and the analyses strategy.26,130 
1. Survival bias: In all the studies, there is an inclusion criterion of surviving up to 24 
hours of age (and up to 72 hours of age in paper IV) to be included in the analysis. 
This introduces a survival bias as the infants have to survive to be included. In paper 
I, we have used a composite outcome of PDA surgery or death and a time-to-event 
approach. This aids in approaching the high mortality rate in extremely preterm 
infants the first few days and weeks as well as accounting for the time the infant was 
at risk for PDA surgery after pharmacological PDA treatment, until they were 
operated or 90 days of age. By this approach, underestimation of the risk of surgery in 
the early treatment group (having the highest mortality, see Figure 5.1.1 in methods) 
is avoided. In paper II, the same approach is applied with the composite outcome of 
BPD or death to account for mortality. In paper III, only survivors to school-age were 
included and survival bias was not an issue. In paper IV, Kaplan Meier curves 
allowed for censoring at time of death.132 Here the data show that infants need to 
survive to have PDA treatment, as the infants not treated who later died had an 
echocardiographical PDA severity which was similar to the severity seen in infants 
that were later treated for PDA. The infants not treated who later died, would 
probably have been treated if they had survived. Furthermore, it becomes evident that 
infants have to survive to undergo PDA surgery, as none of the operated infants in the 
cohort in paper IV died before 40 weeks of gestation. In paper I, there were infants 
who died after PDA surgery, indicating that pre- and post- operative care may have 
improved between 2004-2007. 
2. Selection bias: In paper I, the risk of BPD was lower in the infants treated later (<7 
days) compared to infants treated early (0-2 days), despite the early group having a 
shorter duration of mechanical ventilation. This can be explained by selection bias, 
infants treated late are treated in the window of opportunity for NSAID treatment as 
discussed earlier. In paper II, the differences in access to PDA surgery may have 
introduced a bias which can be associated with the increased risk of BPD in regions 
with higher proportion of PDA treatment and higher PDA surgery rates. In paper I 
and III, region of birth was associated with timing of PDA treatment as well as 
incidence of PDA surgery. In paper III, the outcome of neurodevelopmental outcome 
was not associated with region. Nonetheless, clustering was accounted for in the 
analyses in both studies. (se methods section). In paper IV, selection bias may have 
been introduced as the clinician in charge of the infant was not blinded to the 
biomarker results.  
3. Misclassification bias: By definition107 the studies in this thesis (paper I-IV) do not 
have a misclassification bias as the categories of exposures are clear, i.e. 
pharmacological PDA treatment in paper I, pharmacological and/or surgical PDA 
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treatment in paper II and in paper IV an echocardiographically determined hsPDA. In 
papers II and III, the comparison group are infants not treated for PDA.  As the 
severity of the PDA is not accounted for in papers I-III due to non-availability of 
echocardiographical data, there is a risk of misclassification from the point of view of 
PDA severity. The control groups of infants not treated are hetergenous, there are 
probably infants that had significant PDA shunts, not treated or treated conservatively 
(CPAP or diuretics). This is a methodological problem in all the studies in this thesis. 
In paper IV, the echocardiographic data reveals this and furthermore reveals another 
problem, i.e. the definition of the hsPDA is unclear.   
6.2.2 Confounding 
The data sets allowed for adjustments for various covariates and confounders in the analyses 
of all the four studies. There were limitations though. In paper II, the propensity score only 
included perinatal and early neonatal factors, and not information on the severity of the 
respiratory distress and time sequence of neonatal morbidities (such as infections) as this was 
not collected. The propensity score has to include factors occurring before PDA treatment 
and as the detailed temporal relationship was not known, these mentioned factors could not 
be included. This is a limitation in understanding the association of PDA treatment outcomes 
and especially BPD and residual confounding or confounding by indication cannot be 
excluded in that study. In paper III, confounding by indication or residual confounding cannot 
either be excluded as a contributing factor to the association between primary PDA surgery 
and later risk of NDI and lower FSIQ. Confounding by indication has in other papers been 
suggested as a potential explanation of the association between PDA surgery and adverse 
developmental outcome.130 
6.2.3 Power 
As shown in table 6.2.1 above, the calculated power for studies I, III and IV was appropriate 
for the hypotheses tested.  In paper III, there were issues that may be explained by limited 
power.  In the analysis, IVH grade 3 or higher was neither significantly associated with NDI, 
nor with FSIQ at 6.5 years of age, which might be explained by limited power especially in 
the case of FSIQ. In paper IV, the subgroup analysis is limited due to lack of power and 
posthoc analysis not possible on the echocardiographic data.  
6.2.4 Time-dependencies and temporal relationships  
In all the papers the importance of time dependencies and the time sequence of morbidities is 
emphasized. In paper I, the time at risk for PDA surgery has to be identified and accounted 
for in the analysis. This is fulfilled with the COX proportional hazards regression model.  In 
paper II, it is a clear limitation that the temporal relationships were not known for certain 
neonatal morbidities. This was of methodological reasons not possible, firstly the exact dates 
of diseases were not known, such as sepsis, or start and stop date of each episode of 
mechanical ventilation. Therefore, these factors were not included in the propensity score, 
which predicted PDA treatment as they have to occur before treatment. Furthermore, this can 
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be a source of confounding. In paper III, the same methodological problem of temporal 
relationship was encountered and furthermore, the confounders were more of mediators as 
they encountered after the exposure but before the outcome (example of postnatal steroids 
and BPD described in background-epidemiology chapter). In paper IV, the longitudinal 
echocardiographies enabled us to measure shunt time and verify PDA closure. In the analysis 
of the PDA closure rate, the Kaplan Meier curves allow for censoring because of death or loss 
to follow-up.132 As extremely preterm infants have a high mortality rate during the first 
weeks, this is advantageous. All these factors have been discussed in previously published 
papers on methodological consideration in PDA studies.(see above) 
6.2.5 Validity 
The internal validity of the studies in this thesis is relatively high, if the considerations 
described in the discussion earlier on the methodological concerns is taken into account. 
External validity, that is how the results can be generalized, is appropriate.  The cohorts are 
representative for modern neonatal intensive care population which strengthens the external 
validity, although the PDA treatment strategies are changing. In paper III, the cognitive 
results (FSIQ) of the extremely preterm infants were categorized according to the distribution 
(SD´s of FSIQ) of the matched control children recruited for the original EXPRESS study.15 
This increases the generalizability of the results to other similar highly educated populations. 
The external validity of paper IV is strengthened by the number of immature infants in the 
cohort with both cardiac biomarkers and echocardiographic evaluations of ductal severity as 
24% are born < 25 weeks.  
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7 CONCLUSIONS 
PDA treatment incidence 
• There is a large variation in PDA treatment strategies in very preterm infants, in 
Europe which is not explained by associated variation in perinatal risk factors for 
PDA. 
Immaturity 
• Gestational age is the most important predictor for PDA treatment. 
• Spontaneous PDA closure rate is higher than earlier observed in extremely preterm 
infants (from 25 weeks of gestation). 
• Infants born <25 weeks of gestation have high PDA treatment rates and therefore the 
spontaneous closure rate was not possible to establish. 
Timing of PDA treatment 
• Timing of pharmacological treatment is not associated with risk of later need for PDA 
surgery or death. 
• Later PDA treatment is not associated with increased risk for BPD. 
• Later start of PDA treatment, possibly reduces the risk of unnecessary NSAID 
treatment and thereby exposure to a potentially toxic drug. 
• Early PDA surgery (at <10 days of age) may be a contributing factor in the 
association between PDA surgery and adverse neurodevelopmental outcome. 
Outcomes after PDA treatment 
• Infants treated for PDA, compared to those not treated, are at higher risk of BPD or 
death in all regions.  
• Survival without major neonatal morbidity is not related to PDA treatment. The 
potential association between PDA and BPD is complicated and not easy to 
disentangle in cohort studies. 
• PDA surgery after prior pharmacological treatment and at a later age in life is not 
associated with adverse neurodevelopmental outcome. 
Biomarkers  
• NT-proBNP biomarker is a possible proxy for ductal severity and can be helpful in 
combination with clinical and echocardiographic markers in evaluating need of PDA 
treatment. 
• cTnT is neither associated with ductal severity, as estimated with echocardiographic 
markers, nor PDA treatment in the neonatal period.  
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Methodological considerations  
• Defining the PDA as an exposure is of importance and the most relevant exposure is 
probably the magnitude and duration of the PDA shunt.  
• Time-dependent analysis strategies, and analysis of sequential disease burden is 
important in studies on PDA as an exposure for later morbidities. 
• Conservative treatment should be distinguished from no treatment and evaluated in 
the same manner as pharmacological and surgical PDA treatment.  
• There is a need to standardize PDA treatment, but first optimal placebo-controlled 
trials on PDA management are needed for further optimizing evidence-based care of 
extremely preterm infants.   
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8 IMPLICATIONS 
The studies in this thesis have identified several areas of concern in the diagnostics and 
treatment of the PDA. There is large variation in PDA strategies between units and data was 
not collected on ductal severity in papers I-III. Neither our cohort studies, nor randomized 
trials on PDA treatment have been able to support a causal relationship between PDA and 
adverse outcomes. Nevertheless, the theoretical rationale and clinical experience support that 
the PDA should be respected and not treated as an innocent bystander, but more 
understanding is needed. PDA diagnostics and management need to be studied in optimally 
designed trials. Furthermore, this should be conducted as non-invasively as possible as 
extremely preterm infants belong to a very vulnerable population. 
The first step is to be taken in routine clinical care. We need to start registering the diagnostic 
markers and diagnoses with more precision, to help distinguishing between infants with a 
non-significant PDA that closes spontaneously and infants having a PDA that is treated 
conservatively. In the current studies, the PDA exposure has seldom taken into consideration 
the duration of the shunt. Therefore, longitudinal echocardiographies are needed to confirm 
closure of the duct and to determine the shunt time. This will strengthen the clinical 
understanding and pave the way for future studies. Only a few of the most commonly used 
echocardiographic markers are strongly related to shunt magnitude. In fact, most of the 
markers are correlated to an open duct in the first days of life and not beyond the first week. 
Gestational age is the strongest predictor of PDA treatment and future studies should focus on 
infants born at less than 26 weeks. Other diagnostic methods could be helpful, one of them is 
Near-Infrared Spectroscopy, measuring regional saturation which is important in evaluating 
signs of ductal steal. Optimal scoring systems of PDA severity, where clinical and 
echocardiographic, as well as biomarkers are combined are attractive since PDA severity is 
likely multifactorial. With more precise diagnostics of the PDA, it is probably easier to define 
the risk population and sharpen the inclusion criteria in future studies. What are the optimal 
outcomes to study in context of the PDA? It can be argued that aiming for absolute PDA 
closure is not the most important outcome, rather how the ductal shunt can be modified and 
minimized to reduce clinical morbidities such as IVH, NEC and pulmonary hemorrhage and 
further on BPD.  For example, if we modify the shunt with pharmacological treatment 
without closing the PDA, does the likelihood of extubation increase and thereby reducing the 
duration of mechanical ventilation, which in turn is a strong riskfactor for BPD? 
Understanding the pathophysiology of the PDA and the hemodynamic changes with the usual 
treatment applied in the NICU are central to this. What do long periods of ductal shunting 
with negative effects on the circulation have for consequences? Is it possible to modify these 
effects to decrease risks of IVH, pulmonary hemorrhage, NEC, BPD, ROP and long-term 
adverse neurodevelopment? An example, of the complexity in understanding the clinical 
course and the vulnerability of the population in question, is in infants undergoing PDA 
surgery. They comprise a high-risk population, born at low gestational ages with a complex 
respiratory and circulatory clinical course which could be related to the PDA. Imaging studies 
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have found an association between surgical treatment for PDA and smaller brain volumes at 
term age in this group of infants.133 Smaller brain volumes are indicators of disturbances in 
white matter maturation and associated with adverse neurodevelopmental outcome.134 
Plausible explanations for this could be related to circulation disturbances in association to 
surgery, as both changes in regional cerebral oxygenation and blood flow have been 
described.135-137 But these changes could also be related to the duration and magnitude of 
ductal shunt.138 This understanding of the hemodynamic changes is maybe a key issue in the 
infants and how to reduce morbidities for example NEC.139 The hemodynamic consequences 
of a long standing PDA shunt are not fully understood and studies on long-term cardiac 
outcome are needed.  
The future goal must be to design optimal trials as well as observational studies, with a clear 
definition of the PDA exposure and all treatment modalities considered. In a randomized trial, 
a placebo-arm with either no rescue treatment or at least not before two weeks of age, is 
warranted.  
Moreover, in designing future trials measures to minimize the discomfort of the immature 
infants due to examinations and interventions need to be taken.  Further innovation of non-
invasive methods to evaluate the hemodynamics in extremely preterms is needed.  
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